Protocol  Amendment 2 
Study I D:  214367 
Official Title of  Study:  A Phase II/ III randomized,  multi- center, double-blind, placebo-
controlled study to assess the safety and efficacy of monoclonal antibody VI R-7831 for 
the early treatment of coronavirus disease 2019 (COVID-19) in non- hospitalized patients . 
NCT ID: [STUDY_ID_REMOVED] 
Date of Document:  17-JUN-2021
 
CLINICAL STUDY PROTO COL  
Study Title:  A Phase II/III randomized, multi -center, double -blind, placebo -controlled 
study to assess the safety and efficacy of monoclonal antibody VIR -7831 for 
the early treatment of coronavirus disease 2019 (COVID -19) in non -
hospitalized patients  
Sponsor:  This study is sponsored by Vir Biotechnology, Inc.  
GlaxoSmithKline is supporting Vir Biotechnology, Inc. in the conduct of this 
study.  
Vir Biotechnology, Inc. 
499 Illinois Street, Suite 500  
San Francisco, CA 94158, USA  
Investigational Product:  VIR-7831 (GSK4182136)  
Regulatory Identifying 
Numbers:  IND:  IND #149315  
EudraCT:  2020 -002871 -36 
NCT:  [STUDY_ID_REMOVED]  
IND Number:  149315  
Indication:  Treatment and prevention of coronavirus disease 2019(COVID -19) 
Study Number:  VIR-7831 -5001 (GSK Study 214367)  
: Name:    
Telephone:   
Email:   
Medical Monitor:  Name:    
Telephone:   
Email:    
Protocol Version/Date:  Amendment 2:  17 June 2021 
 
CONFIDENTIALITY STATEMENT  
This document contains confidential information that is the property of Vir Biotechnology Inc. This 
confidential information is being provided for the purpose of evaluating or conducting a clinical study. 
This confidential information will be protected by you and your staff against disclosure to or use by third 
parties, except as necessary for the evaluation or conduct of the study.  
 
Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 2 INVESTIGATOR SIGNATU RE PAGE  
 
VIR BIOTECHNOLOGY, INC  
499 ILLINOIS STREET SUITE 500  
SAN FRANCISCO, CA 94158  
 
STUDY ACKNOWLEDGMENT  
 
A randomized, multi -center, double -blind, placebo -controlled study to assess the 
safety and efficacy of monoclonal antibody VIR -7831 for the early treatment of 
coronavirus disease 2019 (COVID -19) in non -hospitalized patients  
VIR-7831 -5001,  Protocol Amendment  2, 17 June  2021 
This protocol has been approved by Vir Biotechnology, Inc. The following signature 
documents this approval.  
, Pharm D  
Vir , Clinical Research   {See Appended Electronic Signature Page } 
Printed Name   Signature and Date  
 
INVESTIGATOR STATEMENT  
I have read the protocol, including all appendices, and I agree that it contains all 
necessary details for me and my staff to conduct this study as described. I will conduct 
this study as outlined herein and will make a reasonable effort to complete the st udy 
within the time designated.  
I will provide all study personnel under my supervision copies of the protocol and access 
to all information provided by Vir Biotechnology, Inc. I will discuss this material with 
them to ensure they are fully informed about  the drugs and the study.  
 
   
Principal Investigator Printed Name   Signature  
   
  Date  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 3 TABLE OF CONTENTS  
1. PROTOCOL SUMMARY  ................................ ................................ .. 8 
1.1. Synopsis  ................................ ................................ ..............................  8 
1.2. Study Schema  ................................ ................................ ...................  14 
1.3. Schedule of Activities  ................................ ................................ ....... 15 
2. INTRODUCTION  ................................ ................................ ............  19 
2.1. Study Rationale  ................................ ................................ .................  19 
2.2. Background  ................................ ................................ .......................  19 
2.3. Benefit/Risk Assessment  ................................ ................................ .. 20 
2.3.1.  Risk Assessment  ................................ ................................ ...............  21 
2.3.2.  Benefit Assessment  ................................ ................................ ...........  28 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ .....................  28 
3. OBJECTIVES AND ENDPO INTS  ................................ ..................  29 
4. STUDY DESIGN  ................................ ................................ .............  32 
4.1. Overall Desig n ................................ ................................ ..................  32 
4.2. Scientific Rationale for Study Design  ................................ ..............  32 
4.3. Justification for Dose  ................................ ................................ ........  33 
4.3.1.  VIR-7831  ................................ ................................ ..........................  33 
4.3.2.  Placebo  ................................ ................................ ..............................  34 
4.4. End of Study Definition  ................................ ................................ .... 35 
5. STUDY POPULATION  ................................ ................................ ... 36 
5.1. Inclusion Criteria  ................................ ................................ ..............  36 
5.1.1.  Age and Risk Factors  ................................ ................................ ........  36 
5.1.2.  Type of Participant and Disease Characteristics  ..............................  36 
5.1.3.  Sex and Contraceptive/Barrier Requirements  ................................ .. 36 
5.1.4.  Informed Consent  ................................ ................................ .............  37 
5.2. Exclusion Criteria  ................................ ................................ .............  37 
5.2.1.  Medical Conditions  ................................ ................................ ...........  37 
5.2.2.  Prior/Concurrent Clinical Study Experience  ................................ .... 38 
5.2.3.  Other Exclusions  ................................ ................................ ...............  38 
5.3. Lifestyle Considerations  ................................ ................................ ... 38 
5.4. Screen Failures  ................................ ................................ ..................  38 
6. STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
 ................................ ................................ ................................ ..........  39 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 4 6.1. Study Intervention(s) Administered  ................................ .................  39 
6.2. Preparation/Handling/Storage/Accountability  ................................ .. 40 
6.3. Measures to Minimize Bias: Randomization and Blinding  ..............  40 
6.4. Study Intervention Compliance  ................................ ........................  41 
6.5. Dose Modification  ................................ ................................ ............  41 
6.6. Continued Access to Study Intervention after the End of the Study  41 
6.7. Treatment of Overdose  ................................ ................................ ..... 41 
6.8. Concomitant Therapy  ................................ ................................ ....... 41 
6.8.1.  Medication Not Permitted During the Study  ................................ .... 42 
6.8.2.  Permitted Concomitant Medication  ................................ ..................  42 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  .............  43 
7.1. Discontinuation of Study Intervention ................................ ..............  43 
7.1.1.  Temporary Discontinuation  ................................ ..............................  43 
7.2. Participant Discontinuation/Withdrawal from the Study  .................  43 
7.3. Lost to Follow Up  ................................ ................................ .............  43 
8. STUDY ASSESSMENTS AN D PROCEDURES  ............................  45 
8.1. Screening Period  ................................ ................................ ...............  46 
8.1.1.  Medical History  ................................ ................................ ................  46 
8.1.2.  SARS -CoV -2 Diagnostic Testing  ................................ .....................  46 
8.1.3.  Secondary Contact Information  ................................ ........................  46 
8.2. Efficacy Assessments  ................................ ................................ ....... 46 
8.2.1.  Hospitalization and Death Data Collection  ................................ ...... 46 
8.2.2.  Active Monitoring of COVID -19 Progression Phone Call  ...............  47 
8.2.2.1.  Lead -In Phase  ................................ ................................ ...................  47 
8.2.2.2.  Expansion Phase  ................................ ................................ ...............  47 
8.2.3.  Phone Call for Subsequent COVID -19 Illness  ................................ . 47 
8.2.4.  Participant Reported Outcome Assessments  ................................ .... 47 
8.2.4.1.  FLU -PRO Plus Questionnaire  ................................ ..........................  47 
8.2.4.2.  Health -related Quality of Life (SF -12 Hybrid)  ................................ . 48 
8.2.4.3.  Work Productivity and Activity Impa irment (WPAI)  ......................  48 
8.3. Safety Assessments  ................................ ................................ ...........  48 
8.3.1.  Physical Examinations  ................................ ................................ ...... 48 
8.3.2. Vital Signs  ................................ ................................ ........................  49 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 5 8.3.3.  Electrocardiograms  ................................ ................................ ...........  49 
8.3.4.  Cardiac Monitoring  ................................ ................................ ...........  49 
8.3.5.  Virologic Measures  ................................ ................................ ...........  49 
8.3.6.  Clinical Safety Laboratory Assessments  ................................ ..........  50 
8.3.7.  Pregnancy Testing  ................................ ................................ ............  50 
8.4. Adverse Events (AEs), Serious Adverse Events (SAEs) and Other 
Safety Reporting  ................................ ................................ ...............  51 
8.4.1.  Time Period and Frequency for Collecting AE and SAE Information
 ................................ ................................ ................................ ..........  52 
8.4.2.  Assessment of Severity  ................................ ................................ ..... 53 
8.4.3.  Method of Detecting AEs and SAEs  ................................ ................  53 
8.4.4.  Follow -up of AEs and SAEs  ................................ .............................  53 
8.4.5.  Regulatory Reporting Requirements for SAEs  ................................ . 53 
8.4.6.  Pregnancy  ................................ ................................ .........................  53 
8.4.7.  Cardiovascular and Death Events  ................................ .....................  54 
8.4.8.  Adverse Events of Special Interest  ................................ ...................  54 
8.4.8.1.  Infusion -Related Reactions and Serious Hypersensitivity  ...............  54 
8.4.8.2.  Immunogenicity  ................................ ................................ ................  55 
8.4.8.3.  Antibody Dependent Enhancement  ................................ ..................  55 
8.5. Pharmacokinetics  ................................ ................................ ..............  55 
8.6. Genetic s ................................ ................................ ............................  56 
8.7. Biomarkers  ................................ ................................ ........................  56 
8.7.1.  Resistance Analyses  ................................ ................................ ..........  57 
8.8. Immunogenicity Assessments  ................................ ..........................  57 
9. STATISTICAL CONSIDER ATIONS  ................................ .............  58 
9.1. Statistical Hypotheses  ................................ ................................ ....... 58 
9.2. Sample Size Determination  ................................ ..............................  58 
9.3. Analysis Sets  ................................ ................................ .....................  59 
9.4. Statistical Analyses  ................................ ................................ ...........  59 
9.4.1.  General Considerations  ................................ ................................ ..... 60 
9.4.2. Primary Endpoint(s)  ................................ ................................ ..........  60 
9.4.3.  Secondary Endpoint(s)  ................................ ................................ ...... 60 
9.4.4.  Exploratory Endpoint(s)  ................................ ................................ ... 60 
9.4.5.  Safety Analysis  ................................ ................................ .................  61 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 6 9.4.6.  Other Analysis  ................................ ................................ ..................  61 
9.5. Interim Analysis  ................................ ................................ ................  61 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ........  62 
10.1.  Appendix 1: Regulatory, Ethical, a nd Study Oversight 
Considerations  ................................ ................................ ..................  62 
10.1.1.  Regulatory and Ethical Considerations  ................................ ............  62 
10.1.2.  Financial Disclosure  ................................ ................................ .........  62 
10.1.3.  Informed Consent Process  ................................ ................................  63 
10.1.4.  Data Protection  ................................ ................................ .................  63 
10.1.5.  Committees Structure  ................................ ................................ ....... 64 
10.1.6.  Dissemination of Clinical Study Data  ................................ ..............  64 
10.1.7.  Data Quality Assurance  ................................ ................................ .... 65 
10.1.8.  Source Documents  ................................ ................................ ............  66 
10.1.9.  Study and Site Start and Closure  ................................ ......................  66 
10.1.10.  Publication Policy  ................................ ................................ .............  67 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .............  67 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ...........................  69 
10.3.1.  Definition of AE  ................................ ................................ ...............  69 
10.3.2.  Definition of SAE  ................................ ................................ .............  70 
10.3.3.  Definition of Cardiovascular Events  ................................ ................  71 
10.3.4.  Recording and Follow -Up of AE and SAE  ................................ ...... 71 
10.3.5.  Reporting of SAE to GSK  ................................ ................................  73 
10.3.6.  Expedited Reporting to Health Authorities, Investigators and Ethics 
Committees  ................................ ................................ .......................  74 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ............................  74 
10.4.1.  Definitions:  ................................ ................................ .......................  74 
10.4.2.  Contraception Guidance:  ................................ ................................ .. 76 
10.5.  Appendix 5: Genetics  ................................ ................................ ....... 77 
10.5.1 . USE/ANALYSIS OF DNA  ................................ ..............................  77 
11. REFERENCES  ................................ ................................ .................  81 
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 7 LIST OF TABLES  
Table  1: Lead -In Phase: Schedule of Activities  ................................ ..............  15 
Table  2: Expansion Phase: Schedule of Activities  ................................ .........  17 
Table  3: Overview of Study Intervention  ................................ .......................  39 
Table  4: Protocol -Required Safety Laboratory Tests  ................................ ..... 68 
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 8 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Title:  A randomized, multi -center, double -blind, placebo -controlled study to assess the 
safety and efficacy of monoclonal antibody VIR -7831 for the early treatment of 
coronavirus disease 2019 (COVID -19) in non -hospitalized patients  
Rationale:  
There is an urgent m edical need for therapeutics for the treatment of Severe Acute 
Respiratory Syndrome coronavirus -2 (SARS -CoV -2) infection, the cause of coronavirus 
disease 2019 (COVID -19). Early treatment of mild and moderate disease in outpatients 
could prevent the more s evere sequelae of COVID -19 requiring hospitalization, such as 
respiratory failure, thromboembolic disease leading to pulmonary embolism and stroke, 
arrhythmias, and shock . Fur thermore, a potent treatment given early in disease could 
ameliorate the severity  and duration of COVID -19 and potentially reduce transmission . 
Vir Biotechnology, Inc. (Vir) has developed a fully human neutralizing 
anti-SARS -CoV -2 antibody ( Pinto et al. 2020 ), VIR -7831 (GSK4182136), which has an 
Fc-modification (“LS”) that is designed to improve bioavailability in the respiratory 
mucosa (Hope et al. 2019 ) and increase half -life (Ko et al. 2014). 
The Lead -In phase of this study  will serve as the first-in-human  (FIH)  assessment and 
includes  participants  with mild/moderate COVID -19 to assess the safety and tolerability 
of VIR -7831.  Following initial safety assessment in the Lead -In phase , assessment of 
safety and efficacy will commence in the Expansion phase of this study with the aim of 
preventing disease progression in high -risk participants .  
Objectives and  Endpoints:  
Objectives  Endpoints  
Primary   
Evaluate the efficacy of VIR -7831 versus 
placebo in preventing the progression of 
mild/moderate  COVID -19  Proportion of participants  who have 
progress ion of COVID -19 through Day 29  
as defined by:  
1. Hospitalization > 24 hours for acute 
management of illness  
OR 
2. Death  
Secondary   
Safety  
Determine the safety and tolerability of 
VIR-7831 compared  to placebo   
• Occurrence of adverse events (AEs)  
• Occurrence of serious adverse 
events (SAEs)  
• Occurrence of adverse events of 
special interest (AESI)  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 9 Objectives  Endpoints  
Assess the immunogenicity of VIR -7831  • Incidence and titers (if applicable) 
of serum ADA to VIR -7831 
Pharmacokinetics  
Assess the pharmacokinetics (PK) of VIR -
7831 in serum   
• VIR-7831 pharmacokinetics (PK) 
in serum  
Efficacy  
Evaluate the efficacy of VIR -7831 versus 
placebo in preventing the progression of 
mild/moderate COVID -19  
Proportion of participant s who have 
progression of COVID -19 through Day 29 
as defined by : 
• Visit to a hospital emergency room 
for management of illness  
OR 
• Hospitalization for acute 
management of illness  
OR 
• Death  
Evaluate the impact  of VIR -7831 versus 
placebo on the duration and the severity of  
COVID -19 clinical symptoms  •  Mean change in FLU -PRO Plus total 
score comparing Vir -7831 vs. 
Placebo (AUC through Day 7 ) 
• Time to symptom alleviation using 
the FLU -PRO Plus  
Evaluate the efficacy  of VIR -7831 versus 
placebo in reducing SARS -CoV -2 viral load  • Change from baseline in viral load 
in nasal secretions  by qRT -PCR at 
Day 8  
Evaluate the efficacy of VIR -7831 against 
versus placebo in preventing COVID -19 
respiratory disease progression   • Proportion of participants who 
progress to develop severe and/or 
critical respiratory COVID -19 as 
manifest by requirement for and 
method of supplemental oxygen at 
Day 8, Day 15, Day 22, or Day 29  
Evaluate the efficacy of VIR -7831 versus 
placebo in preventing mortality  • 29-day, 60 -day, and 90 -day al l-
cause mortality  
Exploratory   
Evaluate the impact of VIR -7831 versus 
placebo on incidence and duration of time 
on a ventilator, ICU length of stay (LOS), 
and total hospital LOS  • Total number of ventilator days 
from randomization through 90 
days 
• Total intensive care LOS  
• Total hospital LOS  
Evaluate the efficacy of VIR -7831 versus 
placebo in preventing hospitalization from • Proportion of participants 
hospitalized due to non -respiratory Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 10 Objectives  Endpoints  
non-respiratory complications of 
COVID -19 complications of COVID -19 
(cardiac, renal, neurologic, 
hematologic events) by Day 8, Day 
15, Day 22, and Day 29  
Monitor on -treatment emergence of SARS -
CoV -2 resistant mutants against VIR -7831  • Emergence of viral resistance 
mutants to mAb by SARS -CoV -2  
Evaluate the efficacy of VIR -7831 versus 
placebo in reducing duration of SARS -
CoV -2 viral shedding and viremia  • Detection of SARS -CoV -2 in nasal 
secretions by RT -PCR at baseline 
and during follow -up period 
through Day 29  
• Detection of SARS -CoV -2 in blood 
by RT -PCR at baseline and during  
follow -up period through Day 29  
Evaluate the efficacy of VIR -7831 versus 
placebo in reducing SARS -CoV -2 viral load  • Change from baseline in viral load 
in nasal secretions by qRT -PCR 
during follow -up period through 
Day 29  
Evaluate the incidence of respiratory co -
infection with SARS -CoV -2 • Respiratory pathogen detection in 
nasal secretions by PCR on Day 1  
Evaluate the effect of VIR -7831 versus 
placebo on potential biomarkers of host 
response to SARS -CoV -2 • Evaluation of host immune 
responses and explo ratory 
biomarkers related to SARS -CoV -2 
and/or VIR -7831, including 
genetic, cellular, transcriptomic, 
and proteomic parameters  
Measure the impact of VIR -7831 treatment 
on health -related quality of life and time 
away from work due to COVID19  •  Change from baseline in Work 
Productivity and Activity 
Impairment (WPAI) questionnaire  
• Change from baseline for health -
related quality of life according to 
the SF -12 hybrid questionnaire  
Evaluate  the impact of VIR -7831 versus 
placebo on the duration and the severity of 
COVID -19 clinical symptoms  • Mean change in FLU -PRO Plus 
total score (AUC through Days 14, 
21) and Domain scores (AUC 
through Days 7, 14, 21) comparing 
Vir-7831  vs. Placebo  
• The proportion of participants with 
symptom alleviation using the 
FLU -PRO Plus at Days 7, 14, 21  
 
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 11 Overall Design:  
This study is a randomized, double -blind, multi -center, placebo -controlled trial of 
VIR-7831, a monoclonal antibody (mAb) against SARS -CoV -2 for the prevention of 
progression of mild/moderate COVID -19 in high risk adult participants, with interim 
monitoring to allow early stopping for futility, efficacy, or safety. Participants with early, 
mild/moderate COVID -19 who are at high risk for progression of disease will be 
randomized 1:1 to receive a single, intravenous infusio n of either VIR -7831 or equal 
volume saline placebo. Comparisons of safety and efficacy will be based on data from 
concurrently randomized participants.  
Screening assessments will be performed within 24 hours before the first dose. Eligible 
participants w ill be treated in a blinded manner with a single IV dose on Day 1 and 
followed up to 24 weeks.  
The Lead -In phase of this study will serve as the first -in-human assessment and will 
include 20 non -hospitalized participants who have early, mild/moderate COVID -19 and 
are at high risk of disease progression. These participants will be given a single 
intravenous infusion of VIR -7831 and confined for 7 days for safety monitoring. 
Following a safety assessment of unblinded data by an IDMC, the Expansion phase will 
progress, where additional participants with early, mild/moderate COVID -19 and who are 
at high risk of disease progression will be enrolled . 
Brief Summary:  
Lead -In Phase  
The Lead -In phase of the study will evaluate the safety and tolerability of VIR -7831 i n 
participants with early, mild/moderate COVID -19 who are at high risk of progression to 
severe disease. This phase will enroll approximately 10 participants in the active arm and 
10 participants in the placebo arm. Participants will be monitored in an in -patient setting 
for a minimum of 7 days including assessments of respiratory status, oxygenation and 
other vital signs and laboratory evaluations. At the end of 7 days they will either be 
discharged to home  or be formally hospitalized based on investigator  assessment of 
clinical status.  Subjects may be hospitalized or moved to a higher level of care, earlier 
than 7 days, at the investigator’s discretion.  
The first two eligible participants enrolled will be randomized 1:1 to VIR -7831 or 
placebo. These sentinel participants will be dosed and monitored for at least 48 hours 
post-dose and if the investigator has no immediate safety concerns, the remainder of t he 
participants in the Lead -In phase will be dosed (total of 10 per arm inclusive of the 
sentinel participants). Participants will be stratified by age (≤70 vs. >70 years old ) and 
symptom duration (≤3 days vs. 4 -5 days) .  
During dose administration vital s igns will be monitored every 15 minutes over the 
1-hour IV infusion. Vital signs will also be monitored every hour after infusion for 
2 hours  and again at 6 hours after infusion . Vital signs, ECG, symptom -directed physical 
examinations(s), and AEs will be reviewed by the investigator. After discharge on Day 8, 
participants will be actively monitored by daily telephone calls (except on in-clinic  visit 
days) through Day 1 5 for AEs and worsening of COVID -19. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 12 Starting at Week 8 , participants will be monitored m onthly via phone call to assess for 
the incidence and of severity of subsequent COVID -19 illness, if any, for a total of 
24 weeks from dosing.  
Timing of visits and frequency of assessments are outlined in the Schedule of Activities , 
Section  1.3. 
Intensive PK and Immunogenicity Sub -study  
All 20 participant s enrolled in the Lead -In (N=10 per arm; VIR -7831 or placebo) will be 
assigned to an immunogenicity sub -study  and have additional  timepoints for PK  blood 
sampling . Serum PK and anti -drug antibodies (ADA) samples will be collected as 
detailed in the Schedule of Activities  (Section 1.3, Table  1). 
Expansion Phase  
The Expansion phase of the study will progress following assessment of available 
unblinded safety data from the Lead -in phase (N=10 per arm through Day 15  of 
follow -up) by an IDMC. Outpatient p articipants  with early mild/moderate COVID -19 
who are at high  risk for progression to severe disease will be randomized in a 1:1 ratio to 
receive a single IV infusion of VIR -7831 or placebo.  
Participant s will be monitored through at least 2 ho urs post -dose prior to discharge from 
the study unit. During dose administration vital signs will be monitored every 15 minutes 
over the 1 -hour IV infusion. Vital signs will also be monitored every  hour after infusion 
for 2 hours . Participants  will subsequ ently be actively monitored on an outpatient basis 
with in -person study visits at Weeks 1, 2, 3, and 4 and daily telephone calls (except on 
in-clinic  visit days ) through Day 1 5 for AEs and worsening of COVID -19. Serum PK and 
anti-drug antibodies (ADA) samples will be collected as detailed in the Schedule of 
Activities (Section 1.3,  Table  2). 
Starting at Week 8 , participants  will be monitored monthly via  phone call to assess for 
the incidence and of severity of subsequent COVID -19 illness, if any, for a total of 
24 weeks  from dosing.  
Immunology Assessment Sub -study  
Participants  in the Lead -In phase will have blood col lection s for the isolation of 
peripheral blood mononuclear cells (PBMCs)  as part of the required sub -study to explore 
the host immune response and potential biomarkers of infection .  
At select participating sites in the Expansion Phase , participants may consent to an 
optional  sub-study . Subjects who consent to the optional sub -study will have blood 
collection for the isolation of PBMCs.   
The timepoints for blood collection for the sub -study are outlined in the Schedule of 
Activities (Section 1.3 , Table  2). The sub-study will be done at selected sites  in the 
United States  only. All 20 subjects in the Lead -In Phase will par ticipate in the sub -study. 
Approximately, 40-100 participants will be enrolled in the optional sub -study  in the 
Expansion Phase .  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 13 Number of Participants:  
Lead -In Phase  
Approximately 10 p articipant s in the placebo arm and approximately 10 p articipants  in 
the treatment arm.  
Expansion  Phase  
Approximately 670 participants  in the placebo arm and approximately 670 participants  in 
the treatment arm.  
Intervention  Groups and Duration:  
Screening assessments will be performed within 24 hours prior to randomization. Eligible 
participants  will be treated in a blinded manner with a single IV dose on Day 1 and 
followed up to 24 weeks.  
In the Lead -In phase, 20 outpatient participants  with mild/moderate COVID -19 will be 
randomized 1:1 to receive a single IV dose of VIR -7831 or placebo. Partici pants will be 
stratified by age ( ≤70 vs. >70 years old ) and symptom duration ( ≤3 days vs. 4 -5 days) . 
Participants  enrolled in the Lead-In phase  of the study will be closely monitored in an 
in-patient setting for a minimum of 7 days. At the end of 7 days they will either be 
discharged to home  or be formally hospitalized based on investigator assessment of 
clinical status.  Subjects may be hospitalized or moved to a higher level of care, earlier 
than 7 days, at the investigator’s discretion.  
In the Expansion  phase, participan ts with mild/moderate COVID -19 will be randomized 
1:1 to receive a single IV dose of VIR -7831 or placebo.  
Participants in the Expansion phase will be stratified by the following criteria:  
1. Age: ≤70 vs. >70 years old  
2. Duration of COVID -19 symptoms: ≤3 days vs. 4 -5 days 
In addition, randomization will be stratified by region of the world  to protect against 
imbalances within specific regions  which may have different standards of care.  
Independent Data Monitoring  Committee  (IDMC)  
An IDMC will a ctively monitor interim unblinded safety (Lead -In phase) and interim 
unblinded safety and efficacy data (Expansion phase) to make recommendations to  Vir 
regarding ongoing study conduct as detailed in the IDMC Charter. The IDMC members 
will include physicians with relevant medical training and one statistician. As noted 
above, the IDMC will review unblinded safety data from the Lead -In phase of the study 
prior to initiation of the Expansion phase. In addition, the IDMC will perform regular 
safety rev iews during the Expansion phase.  
The first safety review in the Expansion phase  will include available safety and 
tolerability data though Day 1 5 from a total of 60 participan ts (30 per arm). If deemed  
necessary, an additional safety review will be conduc ted after  approximately  100 
additional participants  are enrolled (50 per arm)  to review safety and tolerability data 
through Day 1 5. IDMC members will also review all SAEs via draft CIOMS when they 
become available. Finally, two interim analys es (IA) will be conducted at approximately Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 14 41% of participants enrolled and approximately 64% of participants enrolled  to evaluate 
safety, futility, and efficacy  based on data through Day 29 for these participants . 
Additional details regarding the IDMC process will be available in relevant IDMC 
documents.  
Joint Safety Review Team (JSRT)  
A Joint Safety Review Team (JSRT) comprised of team members from clinical research, 
pharmacovigilance  and statistics will determine if a safety concern identified during 
instream blinded  data review needs to be escalated to the IDMC. The IDMC will act in 
accordance with the process defined in the IDMC Charter.  
1.2. Study Schema  
Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 15 1.3. Schedule of Activities  
Table  1: Lead -In Phase: Schedule of Activities  
Study Stage  Screening  In-patient  Follow -up Period  
Study Visit Week    W2 W3 W4 W6 W8 W12  W16h W20  W24 
(EOS/EW)  
Study Visit Day ± Visit Window  D-1 D1 D2 D5 D8 D11 D15±1 D22±1 D29±2 D43±3 D57±4 D85±7 D113 ±7 D141 ±7 D169 ±7 
Informed consent  X               
Demography  X               
Medical history  X               
Inclusion/exclusion criteria  X               
Physical examinationa Xa Xa (daily)  Xa Xa Xa       
Body weight & height  X               
Vital signs b  
(including O2 saturation)  X Xb X (every 8 hrs)   X X X      X 
Local safety lab assessments  X Xj Xj X X           
Laboratory assessments (central)   Xd X X X  X X X       
SARS -CoV -2 diagnostic test i 
(point -of-care or local laboratory test)  Xi               
Pregnancy test X              X 
Electrocardiogram  X X (daily)            
Randomization   X              
Study drug administration   X              
Blood sample for PK analysis   Xc X X X  X  X X X X  X X 
Blood sample for anti -drug antibody  Xd       X   X  X X 
Blood sample for  
anti-SARS -CoV -2 antibody  Xd   X  X  X   X   X Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 16 Table  1: Lead -In Phase: Schedule of Activities (Continued)  
Study Stage  Screening  In-patient   Follow -up Period  
Study Visit Week    W2 W3 W4 W6 W8 W12  W16h W20  W24 
(EOS/EW)  
Study Visit Day ± Visit Window  D-1 D1 D2 D5 D8 D11 D15±1 D22±1 D29±2 D43±3 D57±4 D85±7 D113 ±7 D141 ±7 D169 ±7 
Blood sample for virology   Xd   X  X  X       
Blood sample for FcR and IgG analysis  
(optional test)  Xd              
Blood sample for RNA Paxgene  
(optional test)  Xd   X           
Nasopharyngeal swab for virology   Xd  X X X X X Xg       
Symptom self -assessment (Flu -PRO  
Plus)  X (daily through Day  21)  X  X X    
Phone call for active COVID -19 
monitoringe   X (daily)e         
Phone call for subsequent COVID -19 
illness   X X X X  
Review/record AEs f Xf 
Concomitant medications  X 
Blood sample for exploratory 
immunology   Xd   X           
PBMC sample for immunology   Xd       X      X 
a Complete  physical examination should be performed on Day 1; all other visits should be symptom -directed physical examinations 
b Vital signs on Day 1 should be recorded prior to dose administration, every 15  min during IV infusion, and  at 1, 2 and 6 hours after  end of  infusion.   
c On Day 1, sample collection will occur pre -dose and at the end of infusion , 1, 2, 6, and 12 hours following end of infusion  
d On Day 1, sample collection will occur pre -dose  
e Daily starting on Day 9, n o phone call conducted on in -clinic visit days  
f Adverse events will be assessed up to Week 12.  Serious adverse events (SAEs) will be assessed up to Week 24 
g If nasopharyngeal swab sample is positive  for SARS -CoV -2 by RT -PCR  at Week 4 additional nasopharyngeal  swab samples may be collected up to Week 24 
h Week  16 is planned as site phone call to participants  only 
i Participants may be tested at  screening if symptom  onset ≤ 5 days  
j Urine for albumin to creatinine ratio should  be collected pre -dose on Day 1 and on Day 2  and performed locally  
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 17 Table  2: Expansion Phase: Schedule of Activities  
Study Stage  Screening  Dosing  Follow -up Period  
Study Visit Week   W1 W2 W3 W4 W8i W12  W16i W20  W24 
(EOS/EW)  
Study Visit Day ± Visit Window  D -1 D1 D5 D8±1 D11±1 D15±1 D22±1 D29±2 D57±4 D85±7 D113 ±7 D141 ±7 D169 ±7 
Informed consent  X             
Demography  X             
Medical history  X             
Inclusion/exclusion criteria  X             
Physical examinationa Xa Xa  Xa  Xa Xa Xa      
Body weight & height  X             
Vital signs (including O2 saturation)  X Xb  X  X X X     X 
Local safety lab assessments  Xk             
Laboratory assessments (central)   Xd  X  X X X      
SARS -CoV -2 diagnostic test j 
(point -of-care or local laboratory 
test) Xj             
Pregnancy test X            X 
Electrocardiogram (Pre -dose)   X            
Phone call for active COVID -19 
monitoringe  X (daily)e        
Randomization   X            
Study drug administration   X            
Blood sample for PK analysis   Xc  X  X  X  X  X X 
Blood sample for anti -drug antibody  Xd      X  X  X X 
Blood sample for anti -SARS -CoV -2 
antibody   Xd  X  X  X  X   X 
Blood sample for virology   Xd  X  X  X      Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 18 Table  2: Expansion Phase: Schedule of Activities (Continued)  
Study Stage  Screening  Dosing  Follow -up Period  
Study Visit Week   W1 W2 W3 W4 W8i W12  W16i W20  W24 
(EOS/EW) 
Study Visit Day ± Visit Window  D -1 D1 D5 D8±1 D11±1 D15±1 D22±1 D29±2 D57±4 D85±7 D113 ±7 D141 ±7 D169 ±7 
Blood sample for FcR and IgG 
analysis  (optional test)   Xd            
Blood sample for RNA Paxgene  
(optional test)   Xd  X          
Nasopharyngeal swab for virology   Xd X X X X X Xh      
Symptom self -assessment  
(Flu-PRO  Plus)  X (daily through Day 21)   X X X    
WPAI Questionnaire   X    X  X X X X X X 
SF-12 Hybrid Questionnaire   X    X  X X X X X X 
Long COVID assessment              X 
Phone call for subsequent COVID19 
illness   X X X X  
Review/record AEs f Xf 
Concomitant medications  X 
Blood sample for exploratory 
immunology   Xd  X          
PBMC sample for immunology g   Xd      X     X 
 
a Complete  physical examination should be performed on Day 1; all other visits should be symptom -directed physical examinations 
b Vital signs on Day 1 should be recorded prior to dose administration, every 15 min during IV infusion of study drug, and at 1 and 2 hour s after infusion 
c On Day 1, sample will be collected pre -dose and at the end of infusion  
d On Day 1, sample collection will occur pre -dose 
e No phone call  conducted  on in -clinic visit days  
f Adverse events will be assessed up to Week 12 post dose. Serious adverse events (SAEs) will be assessed up to Week 24. 
g Optional immunology sub -study  
h If nas opharyngeal  swab sample is positive for SARS -CoV -2 by RT -PCR  at Week 4 additional nasopharynge al swab samples may be collected  up to Week 24 
i Week 8 and Week  16 are planned as site phone call to participants only  
j Participants may be tested at screening if symptom onset ≤ 5 days  
k Except for ABO typing, all other local lab assessments may be perfor med or not as determined necessary by the investigator or required by local regulation s Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831 
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 19 2. INTRODUCTION  
2.1. Study Rationale   
There is an urgent medical need for therapeutics for the treatment of Severe Acute 
Respiratory Syndrome coronavirus -2 (SARS -CoV -2), the cause of coronavirus disease 
2019 (COVID -19). Early treatment of mild and moderate disease in outpatients could 
prevent the more severe sequelae of COVID -19 requiring hospitalization such as 
respiratory failure,  and non -respiratory complications of COVID -19 including 
thromboembolic disease  leading to pulmonary embolism and  stroke, arrhythmias, and 
shock , among others  (Klok 2020 ; Chen 2020 ). Furthermore, a potent treatment given 
early in disease could ameliorate the severity and duration of COVID -19 and potentially 
reduce transmission .  
After  the first four months  of the COVI D-19 pandemic, a number of risk factors 
associated with worse clinical disease were identified. Older age and patients with co -
morbidities were more likely to have severe disease requiring hospitalization or die. 
Therefore, th is study will  enroll  adults at  high risk of medical complications from 
COVID -19, including but not limited to older adults (age ≥ 55 years) and individuals 
aged ≥  18 years with comorbidities associated with worse outcomes, including diabetes, 
obesity (BMI  > 30), chronic kidney disease,  congestive heart failure, chronic obstructive 
pulmonary disease, and moderate to severe asthma  (Garg 2020 ; Petrilli  2020 ).  
A placebo control is required to distinguish the safety and tolerability of VIR-7831 from 
the background signs and symptoms of COVID -19 and to evaluate its potential benefit on 
clinical outcomes. The use of a placebo arm allows for a valid evaluation of any changes 
in efficacy and safety attributable to VIR -7831 versus those attri butable to background 
supportive care given during the study.  
2.2. Background  
A novel betacoronavirus was first reported in December 2019 causing severe pneumonia 
in Wuhan , China.  Since that time, SARS -CoV -2 has spread throughout the world  leading 
to over 16 million confirmed cases and over 650,000 deaths as of J uly 2 7, 2020  
(COV ID-19 dashboard, Johns Hopkins) . There is an urgent need for effective treatment 
throughout the course of illness . Emerging data suggest that morbidity and mortality 
associated with COVID -19 exceeds that of influenza and is impacted by age as well as 
underlying comorbidities that place certain groups at higher risk of poor outcomes. 
Current estimates of overall case fatality rates range from 1.8 to 3.4% with mortality rates 
exceeding 25% for some populations ( Ferguson 2020 ; Bialek 2020 ). Based on current 
experience in China, the UK, and Italy, experts have estimated that approximately 30% of 
those who are hospitalized will require c ritical care and that 50% of those in critical care 
will die. In addition, an age -dependent proportion of those that do not require critical care 
will also die ( Ferguson 2020 ). Mortality rates are likely to be impacted by access to 
appropriate care as inte nsive care unit (ICU) beds and critical care capacity becomes 
overwhelmed. Not only is there a high unmet need for treatment of those with severe 
disease but also for therapies designed to prevent the progression of disease in those with 
early infection . Currently available data suggest that SARS -CoV -2 is associated with a Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831 
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 20 relatively long incubation period, with mean incubation period from exposure to 
symptomatic disease of approximately 5 days with the 95% percentile of the distribution 
at 12.5 days ( Li 2020 ). The median time to progression to severe disease (ICU 
admission/development of ARDS) from onset -of-symptoms has been estimated to be 
12 days (range 8 to 15 days) with a median duration from onset to death or discharge of 
21 days (range 17 to 25 days) ( Zhou 2020 ). In addition, viral loads are highest early in 
the course of disease and tend to fall once severe sequelae have ensued, although remain 
detectable by RT -PCR well into the course of disease ( Zou 2020 ; Wölfel  2020 ). Notably, 
although viral nucleic acid was detected well after symptom resolution in participant s 
with mild infection, shedding of infectious virus in sputum was limited to the first week 
of symptoms ( Wölfel  2020 ). These data suggest that early intervention with a potently 
neutralizing antibody prior to the onset of severe sequelae of disease may effectively 
prevent disease progression and hasten the resolution of disease. Experience with the u se 
of neutralizing  mAbs in the treatment of uncomplicated acute influenza support the idea 
that the time to intervention may be a key determinant of clinical success. Studies that 
enrolled participants  within ≤  5 days ( Ali 2018 ) or <  72 hours ( Hershberger 2019 ) of 
symptom onset were unable to demonstrate statistically significant faster time to 
resolution of symptoms, whereas a study that enrolled patients with symptom onset no 
greater than 48 hours prio r to treatment demonstrated statistically significant reductions 
in time to resolution of symptoms (~2  day reduction compared to the placebo group) 
(Yang 2019 ).  
Given the se factors, a highly potent neutralizing mAb against SARS -CoV 2 administered 
prior to progression to severe disease could prevent progression and lead to faster 
resolution of symptoms.  
Vir Biotechnology, Inc. (Vir) has developed a fully human neutralizing 
anti-SARS -CoV -2 antibody, VIR -7831 (GSK4182136), which contains a 2 amino acid 
Fc-modification (“LS”) that is designed to improve bioavailabil ity in the respiratory 
mucosa and increase half -life. VIR-7831  binds to  a conserved epitope on the 
SARS -CoV  and SARS -CoV -2 spike protein and has been shown to neutralize  
pseudovirus  and live virus in several independent laboratories  (Pinto D et al. 2020 ).  
2.3. Benefit/Risk Assessment  
Information about the reasonably expected adverse events of VIR -7831 may be found in 
the Investigator’s Brochure.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 21 2.3.1.  Risk Assessment  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Study Intervention : VIR -7831  
Infusion reactions including hypersensitivity 
reactions (HSR)  While VIR -7831 is a fully human IgG, 
infusion -related reactions (IRR)  are a 
potential general risk associated with the mAb 
class of therapeutics . Participant  selection:  
Participant s will be excl uded if they have a 
history of hypersensitivity to other monoclonal 
antibodies or any of the excipients present in 
the investigational product.  
 
Monitoring : 
• Guidelines for monitoring relevant adverse 
events encompassing hypersensitivity, 
angioedema and ana phylaxis as well as for 
the management of acute anaphylactic 
shock and minor allergic episodes will be 
in place at investigational sites.  
 
Mitigation :  
• In the sentinel participants and Lead -In 
phase  of the FIH study, vital sign 
measurement will be conducted every 15 
minutes during the planned 1 -hour IV 
infusion  and at 1, 2, and 6 hours post -
infusion . In the Expansion phase, vital 
signs will be monitored every 15  minutes 
over the 1 -hour IV infusion  and at every 
hour after infusion for 2  hours.  
• Infusion related reactions are categorized 
as AESIs  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 22 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
• Investigators will be provided with general 
guidance on management of 
hypersensitivity reactions and such 
reactions will be managed appropriately 
per local guid elines/medical judgment. Pre -
medications will be permitted at the 
investigator’s discretion and will be 
appropriately documented . 
• Investigators will be instructed to 
discontinue IV infusions for participants 
who develop Grade 3 or higher infusion 
reactions .  
• If a participant experiences a Grade 2  IRR, 
investigators will be instructed to pause the 
infusion. The infusion may subsequently 
resume at a slower pace of infusion, at the 
investigator’s discretion, and/or after 
symptomatic treatment (e.g. , anti-
hista mines, IV fluids).  
• IV infusion will be administered in the 
clinic  with staff trained in emergency care 
& resuscitation procedures & emergency 
care kit on hand during treatment & post 
therapy observation periods.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 23 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Immunogenicity  While VIR -7831 is a fully human IgG, the 
development of anti -drug antibodies (ADA) 
that have the potential to impact safety and/or 
efficacy are a potential general risk associated 
with the mAb class of therapeutics  This study will include participant follow -up 
for a period of 24 Weeks (estimated 5 half -
lives) to assess for the potential of 
immunogenicity (measurement of ADA) as 
well as if ADA is potentially causally 
associated with specific safety concerns and/or 
impact efficacy  
Antibody Dependent Enhancement (ADE) 
due to sub -neutralizing levels of VIR -7831 
enhancing fusion or leading to Fc R mediated 
increased viral uptake and replication with 
virus production  This is a concern related to the potential for 
participants  with sub -neutralizing mAb levels 
to experience a higher inci dence of infection 
and/or more severe disease compared to 
participants  with no circulating mAb and/or 
established protective immunity to 
SARS -CoV -2.  
ADE associated with Dengue virus 1 -4 
serotype infections is one of the most widely 
cited examples in which  reinfection with a 
different serotype can, in a minority of 
patients , run a more severe course in the 
setting of limited antibodies generated by 
prior infection.  
The potential for enhanced disease in this 
setting is due to increased uptake of virus by 
FcR-expressing cells, such as macrophages, 
and increased viral replication in these cells. 
Recent data shows that SARS -CoV -2 does not 
replicate efficiently in macrophages 
[Hui 2020 ], suggesting minimal to no  risk of 
ADE via this mechan ism.  Monitoring:  
• This study  will include pa rticipant  follow  
up for a period of 24 Weeks to assess for 
the potential of enhanced disease in the 
context of waning VIR -7831 levels. 
Assessments of the overall incidence of 
COVID -19 (initial or re -infection in the 
case of prevention and treatment, 
respectively) as well as the severity of 
disease will be performed by the IDMC to 
assess for imbalances between mAb - and 
placebo -treated participant s. 
Mitigation:   
• Futility and safety criteria are built into the 
study design to permit early stopping of the 
study for an imbalance in incidence (initial 
or re-infection in the case of prevention and 
treatment, respectively) or severity of 
disease for this study (see Section  10.1.5  
for more details on the IDMC) . Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 24 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
ADE due to enhanced disease pathology from 
viral antigen -antibody related immune 
complex deposition or complement activation  
and immune cell recruitment in target organs  There is the possibility that a large amount of 
antibody that binds, but does not neutralize, 
virus in the presence of a high viral load could 
result in immune complex deposition and 
complement activation in ti ssue sites of high 
viral replication, such as the lungs, vascular 
endothelia, renal or cardiovascular tissue 
[Hamming 2004 ], leading to tissue 
damage/immune complex disease  
This is hypothesized to have contributed to 
inflammation  and airway obstruction 
observed in the small airways of infants who 
received a formalin -inactivated (FI) 
respiratory syncytial virus (RSV) vaccine 
[Polack 2002 ] and in a few cases of fatal 
H1N1 influenza infection [ Wu 2010 ] 
The potential for enhanced disease in this 
setting may be due to low affinity or cross -
reactive antibodies with poor or no 
neutralizing activity  
Triggering of cytokine release by antibody -
virus -FcR interactions although usually 
highly ben eficial due to their direct antiviral 
effects and immune cell recruitment to control 
viral spread in tissues, also has the potential to 
enhance pathologic changes initiated by the 
viral infection  
Observational data from 5000 COVID -19 
patients treated with convalescent plasma, 
although not placebo controlled, is suggestive 
that even polyclonal mixtures of neutralizing 
and non -neutralizing antibodies can be safely 
administered [ Joyner 2020 ] Monitoring:  
• In this study, periodic review of 
clinical signs and symptoms of 
COVID -19, clinical chemistry, adverse 
events, end -organ disease and 
histopathological diag noses (as 
available per routine care) will be 
performed by the J oint Safety Review 
Team to identify potential cases of 
immune complex disease  
• Additional  monitoring in the event a 
participan t develops signs or symptoms 
of cardiac complications (See  
Section  8.3)  
• In addition, the IDMC will be 
instructed to perform periodic data 
review of clinical signs and symptoms 
of COVID -19, clinical chemistry , any 
cardiac assessments, end -organ disease 
and histopathological diagnoses (as 
available per routine care) with the aim 
of identifying imbalances in the study 
arms with respect to worsening of 
COVID -19-related  end-organ 
complications that may reflect 
immune -complex reactions.  
• Assessments of the overall duration 
and severity of COVID -19 will be 
performed by the IDMC to assess for 
imbalances between mAb - and 
placebo -treated participants.  
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 25 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
VIR-7831 shows potent binding in vitro as 
well as neutralization of pseudovirus and live 
virus  thus this risk is deemed to be low.  Mitigation:  
Futility and safety criteria are built in to the 
study design to permit early stopping of the 
study for an imbalance in or severity of disease 
(see Section  10.1.5  for more details on the 
IDMC ) 
Study Procedures   
Infusion site reactions  including 
hypersensitivity reactions  While VIR -7831 is a fully human IgG, 
infusion -related reactions (IRR) are a 
potential general risk associated with the mAb 
class of therapeutics.  Participant selection :  
• Participants  will be excluded if they have a 
history of hypersensitivity to other 
monoclonal antibodies or any of the 
excipients present in the investigational 
product.  
 
 
Monitoring:  
• Guidelines for monitoring relevant adverse 
events encompassing hypersens itivity, 
angioedema and anaphylaxis as well as for 
the management of acute anaphylactic 
shock and minor allergic episodes will be 
in place at investigational sites.  
• For the Lead -In phase of this study, v ital 
sign measurement s will be conducted every 
15 min utes during the planned 1 -hour IV 
infusion and at 1, 2 , and 6 hours  post-
infusion.  For the Expansion phase, vital 
signs will be monitored every 15 minutes 
over the 1 -hour IV infusion and at every 
hour after infusion for 2 hours.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 26 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
• Infusion time can be extend ed at the 
discretion of the Investigator, Sponsor or 
IDMC based on local infusion -related 
symptoms or other safety findings.  
• Joint Safety Review Team reviews will be 
conducted at least every two weeks to 
determine if a significant safety signal of 
severe h ypersensitivity reaction is 
identified. The IDMC will be notified per 
Charter for adjudication.  
Mitigation :  
• Investigators will be instructed to 
discontinue IV infusions for p articipants  
who develop Grade 3 or higher infusion 
reactions  using DAIDS Table for Grading 
the Severity of Adult and Pediatric Adverse 
Events , version 2.1 (July 2017)  Adverse 
Event grading .  
• If a participant  experiences a Grade 2 IRR, 
investigators will be instructed to pause the 
infusion. The infusion may subsequently 
resume at a slower pace of infusion, at the 
investigator’s discretion, and/or after 
symptomatic treatment (e.g. anti -
histamines, IV fluids).   
• Investigators will be provided with general 
guidance on management of 
hypersensitivity reactions and such 
reactions will be managed appropriately 
per local guidelines/medical judgment. Pre -
medications will be permitted at the 
investigator’s discretion and will be 
appropriately documented.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc.  Page 27  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 28 2.3.2.  Benefit Assessment  
Although VIR -7831 has not been studied before in this acutely ill population, there is 
biologic rationale which supports the use of VIR -7831, an antiviral mAb in the early 
treatment of COVID -19 to prevent progression .  
VIR-7831 has been demonstrated in vitro to be a highly potent fully human IgG 
neutralizing SARS -CoV -2 antibody which has the  potential to be an effective therapeutic 
in mild to critically ill patients with COVID -19. VIR-7831 does not bind to normal 
human tissues in the tissue cross -reactivity study and there were no adverse findings after 
2 weeks in the 2 -week repeat dose monke y toxicity study. The no -observed -adverse -
effect -level (NOAEL) in the monkey study was 500 mg/kg, the highest dose tested.  
The study population to be enrolled in this study has a high unmet medical need. 
VIR-7831 may or may not improve the time to clinical response or overall clinical 
outcome in an individual participant with mild or moderate  COVID -19 who participates 
in this study. However, there is potential benefit from their participation in this study 
resulting from their data allowing evaluation of VIR -7831 as a potential treatment for this 
new disease.   
2.3.3.  Overall Benefit:  Risk Conclusion  
The overall benefit -risk assessment takes into account the potential benefit of VIR -7831 
treatment  through the potential  ability  to suppress viral replication and clear infected 
cells.  
Based on the high unmet medical need and considering the measures taken to minimize 
risk to participants participating in this study, the potential risks identified in association 
with VIR-7831 are justified by the anticipated benefits that may be afforded to 
participants with mild to moderate COVID -19. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 29 3. OBJECTIVES AND  ENDPOINTS  
Objectives  Endpoints  
Primary   
• Evaluate the efficacy of VIR -7831 
versus placebo in preventing the 
progression of mild /moderate  
COVID -19 • Proportion of participants who have 
progression of COVID -19 through Day 
29 as defined by:  
1. Hospitalization > 24 hours for acute 
management of illness  
OR 
2. Death  
Secondary   
Safety  
• Determine the safety and tolerability of 
VIR-7831 compared to placebo   
• Occurrence of adverse events (AEs)  
• Occurrence of serious adverse events 
(SAEs)  
• Occurrence of adverse events of special 
interest (AESI)  
• Assess the immunogenicity of 
VIR-7831  • Incidence and titers (if applicable) of 
serum ADA t o VIR -7831  
Pharmacokinetics  
• Assess the pharmacokinetics (PK) of 
VIR-7831 in serum   
• VIR-7831 pharmacokinetics (PK) in 
serum  
Efficacy  
• Evaluate the efficacy of VIR -7831 
versus placebo in preventing the 
progression of mild/moderate 
COVID -19  
Proportion of participants who have progression 
of COVID -19 through Day 29 as defined by:  
•  Visit to a hospital emergency room for 
management of illness  
OR 
• Hospitalization for acute management 
of illness  
OR 
• Death  
• Evaluate the impact of VIR -7831 
versus placebo on the duration and the 
severity of COVID -19 clinical 
symptoms  •  Mean change in FLU -PRO Plus total 
score comparing Vir -7831 vs. Placebo 
(AUC through Day 7 ) 
• Time  to symptom alleviation using the 
FLU -PRO Plus  
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 30 • Evaluate the efficacy of VIR -7831 
versus placebo in reducing SARS -
CoV -2 viral load  • Change from base line in viral load in 
nasal secretions  by qRT -PCR at Day 8  
• Evaluate the efficacy of VIR -7831 
against versus placebo in preventing 
COVID -19 respiratory disease 
progression  • Proportion of participants who progress 
to develop severe and/or critical 
respiratory COVID -19 as manifest by 
requirement for and method of 
supplemental oxygen at Day 8, Day 15, 
Day 22, or Day 29  
• Evaluate the efficacy of VIR -7831 
versus placebo in preventing mortality  • 29-day, 60 -day, a nd 90 -day all cause 
mortality  
Exploratory   
• Evaluate the impact of VIR -7831 
versus placebo on incidence  and 
duration of time on a ventilator, ICU 
length of stay (LOS),  and total hospital 
LOS  • Total number  of ventilator days from 
randomization through 90 days 
• Total intensive care LOS  
• Total hospital LOS  
• Evaluate the efficacy of VIR -7831 
versus placebo in preventing 
hospitalization from non -respiratory 
complications of COVID -19 • Proportion of participants hospitalized 
due to non -respiratory complications of 
COVID -19 (cardiac, renal, neurologic, 
hematologic events) by Day 8, Day 15, 
Day 22, and Day 29  
• Monitor on -treatment emergence of 
SARS -CoV -2 resistant mutants against 
VIR-7831  • Emergence of viral resistance mutants to 
mAb by SARS -CoV -2  
• Evaluate the effic acy of VIR -7831 
versus placebo in reducing duration of 
SARS -CoV -2 viral shedding and 
viremia  • Detection of SARS -CoV -2 in nasal 
secretions by RT -PCR at baseline and 
during follow -up period through Day 29  
• Detection of SARS -CoV -2 in blood by 
RT-PCR at baselin e and during follow -up 
period through Day 29  
• Evaluate the efficacy of VIR -7831 
versus placebo in reducing SARS -
CoV -2 viral load  • Change from baseline in viral load in 
nasal secretions by qRT -PCR during 
follow -up period through Day 29  
• Evaluate the incidence of respiratory 
co-infection with SARS -CoV -2 • Respiratory pathogen detection in nasal 
secretions by PCR on Day 1  
• Evaluate the effect of VIR -7831 versus 
placebo on potential biomarkers of 
host response  to SARS -CoV -2 • Evaluation of host immune responses and 
exploratory biomarkers related to SARS -
CoV -2 and/or VIR -7831, including 
genetic, cellular, transcriptomic, and 
proteomic parameters  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 31 • Measure the impact of VIR -7831 
treatment on health -related quality of 
life and time away from work due to 
COVID19  •  Change from baseline in Work 
Productivity and Activity Impairment 
(WPAI)  questionnaire  
•  Change from baseline for health -related 
quality of life according to the SF-12 
hybrid  questionnaire  
• Evaluate  the impact of VIR -7831 
versus placebo on the duration and the 
severity of COVID -19 clinical 
symptoms  • Mean change in FLU -PRO Plus total score 
(AUC through Days 14, 21) and Domain 
scores (AUC through Days 7, 14, 21) 
comparing Vir -7831  vs. Placebo  
• The p ropor tion of participants with 
symptom alleviation using the FLU -PRO 
Plus at Days 7, 14, 21  
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 32 4. STUDY DESIGN  
4.1. Overall Design  
This study is a randomized, double -blind, multi -center, placebo -controlled trial of 
VIR-7831, a monoclonal antibody (mAb) against SARS -CoV -2 for the prevention of 
progression of mild/moderate COVID -19 in high risk participants, with interim 
monitoring to allow early stopping for futility, efficacy, or safety. Participants with early, 
mild/moderate COVID -19 who are at high risk for pr ogression of disease will be 
randomized 1:1 to receive a single, intravenous infusion of either VIR -7831 or equal 
volume saline placebo. Comparisons of safety and efficacy will be based on data from 
concurrently randomized participants.  
Screening assessme nts will be performed within 24 hours before the first dose. Eligible 
participants  will be treated in a blinded manner with a single IV dose on Day 1 and 
followed up to 24 weeks . 
The Lead -In phase of this study will serve as the first -in-human assessment and will 
include 20 non-hospitalized participants who have early, mild/moderate COVID -19 and 
are at high risk of disease progression. These participant s will be given a single 
intravenous infusion of VIR -7831 and confined for 7 days for safety monitoring. 
Following a safety assessment of unblinded data by an IDMC, the expansion phase will 
progress, where additional participants with early, mild/moderate COVID -19 and who are 
at high risk of disease progression will be enrolled.  
4.2. Scientific Rationale for Study Design  
This study is a two -phase (FIH to phase 2/3)  randomized, placebo -controlled study  to 
evaluate the safety, tolerability, PK, immunogenicity, and efficacy of VIR -7831 
compare d to placebo in the treatment of early  mild/moderate  COVID -19 in adults at high 
risk of medical complications from COVID -19, including but not limited to older adults 
(age ≥ 55 years) and  all individuals  age 18 or  older  with comorbidities associated with 
worse outcomes,  including  diabetes,  obesity (BMI>30), chronic kidney 
disease,  congestive heart failure,  chronic obstructive pulmonary disease, and moderate to 
severe asthma.  The study will  include outpatients with SARS -CoV -2, the virus that 
causes COVID -19, as confirmed by  local  laboratory tests and/or point of care tests.  
The study will include a  Lead -In phase to assess the safety of VIR -7831 compared to 
placebo (10 participant s per arm ). A single dose level designed to provide potential 
therapeutic benefi t will be studied and will be delivered via IV infusion. Participants  will 
be admitted to a study unit and monitored closely for adverse events, changes in 
laboratory parameters and progression (or improvement) in disease  signs 
and symptoms.  This approach is appropriate given the theoretical risk for antibody 
dependent enha ncement of disease, including immune complex formation and deposition 
in tissues, in patients with high viral burden [ Liu 2019 ]. 
Following review of available unblinded safety data through Day 1 5 by the IDMC, the 
study will expand to  enrol l additional participants. The purpose of the Expansion phase 
will be to evaluate the safety and efficacy of VIR -7831 in comparison to the placebo 
control arm. Two interim analyses at approximately 41% of participants enrolled  and Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 33 approximately 64% of participant s enrolled will be conducted to evaluate futility, 
efficacy, and safety based on data through Day 29 for these participants.  To date, t here 
are no approved treatments for mild/moderate COVID -19. A placebo control is required 
to distinguish the  safety and tolerability of VIR -7831 from the background signs and 
symptoms of COVID -19 and to evaluate its potential benefit on clinical outcomes. The 
use of a placebo arm allows for a valid evaluation of any changes in efficacy and safety 
attributable to  VIR-7831 versus those attributable to background supportive care given 
during the study.  
A double -blind design is a standard methodology for randomized, controlled studies to 
avoid bias. Unblinded safety and efficacy data will be reviewed regularly by an IDMC.  
The primary endpoint to assess efficacy of treatment is progression of mild/moderate 
COVID -19 defined by hospitalization >24 hours for acute management of illness or death 
within 29 days of randomization. The transition from outpatient status without  
hypoxemia or oxygen requirement to hospitalization for acute care or death is a clinically 
significant milestone. It is considered to be clinically important to participants and 
physicians alike. A 29 -day period to assess the primary endpoint is appropria te as the 
median time for COVID -19 related hospital admission has been reported to be 7 -11 days 
and the median time to clinical deterioration, 9 -12 days (Zhou  2020 , Huang  2020 ). 
The most significant of the s econdary endpoints is evaluation of whether VIR -7831 can 
shorten the duration or lessen the severity of COVID -19. Demonstration of a n 
improvement in the severity of disease  following administration of VIR -7831 would be 
considered highly clinically meaningful. Other efficacy endpoints related to decrease in 
viral shedding, mortality, and health resource utilization  – length of hospital stay, ICU 
stay, time ventilated – are al so highly clinically relevant and recommended in COVID -19 
trial guidelines ( NICE 2020 ; WHO 2020 ; FDA 2020 ). 
4.3. Justification for Dose  
4.3.1.  VIR-7831  
A single dose of 500 mg was selected for the s tudy based on in vitro neutralization data, 
in vitro resistance data, expected  human PK extrapolated from a study  in cynomolgus 
monkeys, and the results of the GLP monkey toxicology study.  
VIR-7831 neutralized SARS -CoV -2 live virus with an average EC 90 value of 
186.3  ng/mL (range: 125.8 – 329.5 ng/mL) (PC -7831 -0105). In resistance analyses, no 
viral breakthrough was observed through 10 passages at fixed concentrations of antibody 
even at the lowest dose tested ( ~10x EC 50), indicating the potential for VIR -7831 to have 
a high barrier to resistance (PC -7831 -0109).  
Using an increasing concentration selection method to force resistance emergence, 
modest fold changes in EC 50 were observed during viral selection (5 -to 6-fold change in 
EC 50) for some passages (PC-7831 -0109). Sequencing and testing of spike variants from 
these passages using a pseudotyped virus system did not identify causal variants for this 
modest shift in potency. One passage of virus did demonstrate a >10 fold shift in EC 50 
which correlated with an E340A mutation. Further assessment has identified E340A to be 
a monoclonal antibody -resistant mutant ( MARM ) that confers a >100 -fold reduction in 
susceptibility to VIR -7831. Notably, E340 is 100% conserved among available Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 34 SARS -CoV -2 sequences. Due to the binary nature of the resistance selection results, a 
specific inhibitory quotient (IQ) was not informed by the resistance profiling. However, 
as our understanding of the biology of SARS -CoV -2 is currently still limited and very 
few strains are avail able to directly assess breadth of coverage, a conservative IQ (> 10) is 
appropriate in this case.  
The cynomolgus monkey PK from study PK -7831 -0115 was fit to a 2 compartment PK 
model. Human PK parameters were scaled from the cynomolgus monkey using an 
allometric scaling approach for fully human IgGs (allometric coefficient of 0.85 and 1 for 
CL and V, respectively; Deng 2011 ). The predicted serum clearance of VIR -7831 in 
humans is estimated to be 141 mL/day and estimated volume of dis tribution is 6500 mL 
(~93 mL/kg) assuming human weight of 70 kg. The projected human terminal 
elimination half -life is approximately 32 days.  
In order to reduce risk to patients (treatment failure, resistance), the dose was selected to 
ensure that VIR -7831 concentrations in lung are maintained at or above levels anticipated 
to be protective of SARS -CoV-2 infection for the duration of the 28 -day treatment 
window. A dose of 500 mg is expected to maintain serum levels at or above 38.5 µg/mL 
for the duration o f the 28 -day treatment period. Based on the EC 90 (0.33  μg/mL) from the 
highest end of the EC 90 range (PC -7831 -0105), and accounting for the lung:serum ratio 
for IgG (assumed conservative value of 0.25; reported range 0.25 -0.68 for whole lung 
and interstiti al fluid, respectively; Baxter 1994 , Covell  1986 , Datta -Mannan  2019 , Lobo 
2004 ) the serum trough concentration following a 500 mg dose is expected to resul t in 
lung concentrations associated with maximal (> 99%) antiviral activity; > 29 x tissue -
adjusted EC 90 for the duration of the 28 day treatment period. This conservative 
inhibitory quotient (29) in lung is believed to be appropriate to increase potential  for 
treatment success and reduce risk for resistance.  
Additionally, a 500 mg dose is anticipated to result in protective levels of VIR -7831 in 
nasopharyngeal secretions (>5 x tissue adjusted EC 90 assuming NPS:serum ratio of 0.05, 
Lim 2017 ) which could potentially reduce transmission.  
The NOAEL for VIR -7831 was 500 mg/kg, the highest dose tested, when VIR -7831 was 
administered  via IV infusion once a week for 2 weeks  in cynomolgus monkeys 
(TX-7831 -0102). At this NOAEL, preliminary C max and AUC 0-t (AUC from time 0 to 
168hr post -end of infusion following the 2nd dose ) were 13500 μg/mL and 
48200  μg•day/mL, respectively. The human equivalent dose (HED) (HED calculated via 
direct mg/kg conversion according to FDA guidance on proteins admi nistered 
intravascularly with Mr  > 100,000 daltons; FDA 2005 ) is 500 mg/kg or a 30,000  mg 
fixed dose (using human body weight of 60 kg). Using a safety factor of 10, the 
maximum recommended starting dose in humans is approximately 50  mg/kg or a 
3,000 mg fixed dose. Based on the proposed 500 mg human dose, the margins based on 
the HED, C max, and AUC (conservative AUC margin based on partial AUC 0-t from 
TX-7831 -0102 and expected AUC inf in humans) are 60 -, 87-, and 13.6 -fold, respectivel y, 
supporting the proposed clinical dose of 500 mg . 
4.3.2.  Placebo  
There is no established treatment for non-hospitalized  patients  with mild to moderate  
COVID -19, hence a placebo control is required to distinguish the safety and tolerability Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 35 of VIR -7831 from the background signs and symptoms of severe or critical COVID -19 
and to evaluate its potential benefit on clinical outcomes  
4.4. End of Study Definition  
A participant is considered to have completed the study if he/she has completed all 
phases of the study through to Week  24. The end of the study is defined as the date of the 
last contact of the last participant in the study.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 36 5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exempti ons, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria 
apply:  
5.1.1.  Age and Risk Factors  
1. Participant must be  aged 18 years or older AND at high risk of progression of  
COVID -19 based o n presence of one or more of the followin g risk factors:  
diabetes  (requiring medication ), obesity (BMI> 35), chronic kidney disease   
(i.e., eGFR <60 by MDRD ), congestive heart failure  (NYHA class II or more) , 
chronic obstructive pulmonary disease  (history of chronic bronchitis, chronic 
obstructive lung disease , or emphysema with dyspnea on physical exertion) , and 
moderate to severe asthma  (participan t requir es an inhaled steroid to control 
symptoms or has been prescribed a course of oral steroids in the past year)  
OR 
2. Participant ≥ 55 years old, irrespective of co -morbidities.  
a. Note : target enroll ment of  ~15% of participants >70 years old  
5.1.2.  Type of Participant and Disease Characteristics  
3. Participants who have a positive SARS -CoV -2 test result (by any  validated 
diagnostic  test e.g. RT -PCR , antigen based testing  on any specimen type)  
AND  
Oxygen saturation ≥94% on room air  
AND  
Have COVID -19 defined by one or more of the following symptoms: fever, chills, 
cough, sore throat, malaise, headache, joint or mu scle pain, change in smell or 
taste, vomiting, diarrhea, shortness of breath on exertion  
AND  
Less than or equal to 5 days from onset of symptoms  
5.1.3.  Sex and Contraceptive/Barrier Requirements  
4. No gender restrictions  
5. Female participants must meet and agree to abide by the following contraceptive 
criteria. Contraception use by women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.  
 
A female participant is eligible to participate if sh e is not pregnant or 
breastfeeding, and one of the following conditions applies:  
a. Is a woman of non -childbearing potential (WONCBP) as defined in  
Section  10.4. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 37 OR 
b. Is a WOCBP and using a contraceptive method that is highly effective, with a 
failure rate of <1%, as described in Section  10.4 of the protocol during the 
study intervention period and for up to 24 weeks  after the last dose of study 
intervention. The investigator should evaluate potential for contraceptive 
method failu re (e.g., noncompliance, recently initiated) in relationship to the 
first dose of study intervention.  
A WOCBP must have a negative highly sensitive pregnancy test (urine or serum 
as required by local regulations) before the first dose of study intervention . 
See Section  8.3.7  Pregnancy Testing of the protocol.  
− If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a 
serum pregnancy test is required. In such cases, the participant must be excluded 
from participation if the serum pregnancy result is positive.  
− Additional requirements for pregnancy testing during and after study intervention 
are located in Section  1.3 of the protocol.  
The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woma n with an early 
undetected pregnancy  
5.1.4.  Informed Consent  
6. Capable of giving signed informed consent as described in Section  10.1 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.  
OR 
If participants are not capable of giving written informed c onsent, alternative 
consent procedures will be followed as described  in Section  10.1.3 . 
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
5.2.1.  Medical Conditions  
7. Currently hospitalized or judged by the investigator as likely to require 
hospitalization in the next 24 hours  
8. Symptoms  consistent with severe COVID -19 as defined by shortness of breath at 
rest or respiratory distress or requiring supplemental oxygen.  
9. Participants  who, in the judgement of the investigator are likely to die in the next 
7 days.  
10. Severely immunocompromised par ticipants , including but not limited to cancer 
patients actively receiving  immunosuppressive chemotherapy or immunotherapy, 
those with a  solid organ transplant or allogeneic stem cell transplant within the 
last 3  months, or those having  conditions requirin g the use of systemic  
corticosteroids equivalent to ≥ 0.5 mg/kg  of body weight  per day of prednisone 
within 6  weeks  of randomization  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 38 11. Known hypersensitivity to any constituent present in the investigational product  
12. Previous anaphylaxis or hypersensitivity t o a monoclonal antibody  
5.2.2.  Prior/Concurrent Clinical Study Experience  
13. Enrollment in any investigational vaccine study  within the last 180 days or any 
other investigational drug study within 30  days prior to Day 1 or within 
5 half-lives of the investigational compound, whichever is longer.   
14. Enrollment in any trial of an investigational vaccine for SARS -CoV -2 . 
5.2.3.  Other Exclusions  
15. Receipt of any vaccine within 48 hours  prior to enrollment.  Receipt of a 
SARs -CoV -2 vaccine prior to randomization  at any timepoint . Vaccination 
(including vaccination for SARS -CoV -2) will not be allowed for 4 weeks after 
dosing.  
16. Receipt of convalescent plasma from a recovered COVID -19 patient  or 
anti-SARS -CoV -2 mAb  within the last 3 months.  
17. Participants who, in the judgment of the investi gator, will be unlikely or unable to 
comply with the requirements of the protocol through Day 2 9 
5.3. Lifestyle Considerations  
Lifestyle considerations are not applicable to this study.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet  the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes 
demography, screen failure details, eligibility criteria,  any protocol deviations  and any 
serious adverse events (SAE s). Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 39 6. STUDY INTERVENTION (S) AND CONCOMITANT 
THERAPY  
Study intervention  is defined as any investigational intervention (s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant accordi ng 
to the study protocol.  
6.1. Study Intervention( s) Administered  
Overview of study interventions is provided in  Table  3. Detailed instructions for the 
adminis tration of study drug will be provided in a separate pharmacy manual  
Table  3: Overview of Study Intervention  
Arm Name  VIR-7831  Placebo  
Intervention Name  VIR-7831  Placebo to VIR -7831  
Type  Biologic  Placebo to Biologic  
Dose Formulation  Solution in single -use vial 
(25 mg/mL)  Sterile 0.9% (w/v) sodium chloride 
solution  
Unit Dose 
Strength(s)  250 mg/vial (250 mg/10 mL)  Not applicable  
Dosage Level(s)  500 mg once  Once  
Route of 
Administration  IV infusion  IV infusion  
IMP and NIMP  IMP IMP 
Sourcing  VIR-7831 will be provided 
centrally by the Sponsor.  Saline for placebo will be provided 
centrally by Sponsor.  
Dosing instructions  Approximately 1 -hour infusion 
time will be used to administer 
the total dose volume.  Approximatel y 1-hour infusion 
time will be used to administer the 
total dose volume.  
Packaging and 
Labelling  Study intervention will be 
provided in a single -use vial in 
an individual carton and 
labelled as required per country 
requirement.  Saline will be provided in a single -
use vial and l abelled as required 
per country requirement  
Current/Former 
Name(s) or Alias(es)  VIR-7831, GSK4182136  Not applicable  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 40 6.2. Preparation/Handling/Storage/Accountability  
Instructions for the preparation of study drug will be provided in a se parate pharmacy 
manual.  
1. The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study intervention received and any 
discrepancies are reported and resolved before use of the study interventio n. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention. All study 
interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or a utomated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  
3. The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study interventi on accountability, reconciliation, and 
record maintenance ( i.e., receipt, reconciliation, and final disposition records).  
4. Further guidance and information for the final disposition of unused study 
intervention are provided in the  pharmacy manual .  
Under normal conditions of handling and administration, study intervention is not 
expected to pose significant safety risks to site staff . Take adequate precautions to avoid 
direct eye or skin contact and the generation of aerosols or mists. In the case of 
unint entional occupational exposure notify the monitor, medical monitor  and/or Sponsor  
study contact.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
All participants will be centrally randomized using an Interactive Web Response System 
(IWRS). Before the  study is initiated, the log in information and directions for the IWRS 
will be provided to each site.  
Participants will be randomized in a 1:1 ratio to receive study intervention. Investigators 
will remain blinded to each participant’s assigned study inte rvention throughout the 
course of the study. In order to maintain this blind, the study pharmacist will be 
responsible for the reconstitution and dispensation of all study intervention and will 
endeavor to ensure that there are no differences in time taken  to dispense following 
randomization.  
The IWRS will be programmed with blind -breaking instructions. In case of an 
emergency, the investigator has the sole responsibility for determining if unblinding of a 
participants’ intervention assignment is warranted.  Participant safety must always be the 
first consideration in making such a determination. If the investigator decides that 
unblinding is warranted, the investigator should make every effort to contact the Sponsor 
prior to unblinding a participant’s interv ention assignment unless this could delay 
emergency intervention of the participant. If a participant’s intervention assignment is 
unblinded , the Sponsor must be notified within 24 hours after breaking the blind. The 
date and reason that the blind was brok en must be recorded in the source documentation 
and case report form, as applicable.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 41 Unblinded monitors and in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to unblinded study intervention records at the site(s) to verify th at 
randomization/dispensing has been done accurately.  
A participant may continue in the study if that participant’s intervention  assignment is 
unblinded  
GlaxoSmithKline ’s (GSK’s ) Pharma  Safety staff may unblind the intervention  
assignment for any participa nt with an SAE. If the SAE requires that an expedited 
regulatory report be sent to one or more regulatory agencies, a copy of the report, 
identifying the participant’s  intervention  assignment, may be sent to investigators in 
accordance with local regulatio ns and/or GSK policy.  
6.4. Study Intervention  Compliance  
Participants will receive VIR -7831 or placebo directly from the investigator or designee, 
under medical supervision. The date and start and stop times of the dose administered 
will be recorded in the sour ce documents. The dose of study intervention and study 
participant identification will be confirmed at the time of dosing by a member of the 
study site staff other than the person administering the study intervention . 
6.5. Dose Modification  
This is a single dose study  and dose modifications are not applicable. See Section  7.1 for 
instructions to discontinue study treatment for safety reasons.  
6.6. Continued Access to Study Intervention after the End of the 
Study  
COVID -19 is an acute illness and participants are not expected to need continued access 
to VIR -7831 after the end of the study  
6.7. Treatment of Overdose  
No specific treatment is recommended for an overdose. The treatment physician may 
provide supportive measures depending on the symptoms.  
In the event of an overdose, the  treating physician  should:  
1. Contact the medical monitor immediately.  
2. Closely monitor the participant for AE/SAE and laboratory abnormalities . 
3. Document the quantity of the excess dose as well as the duration of the 
overdosing in the CRF.  
6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, 
recreational drugs, vitamins, and/or herbal s upplements ) or other specific categories of 
interest  that the participant is receiving at the time of enrollment or receives during the 
study must be recorded along with:  
• reason for use  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 42 • dates of administration including start and end dates  
• dosage information including dose and frequency  
The medical monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.  
6.8.1.  Medication N ot Permitted During the Study  
Given accumulating evidence around the risks associated with the use of 
hydroxychloroquine and chloroquine and absence of defined benefit, these will NOT be 
considered standard of care, and are prohibited over the course of the study.  
Receipt of convalescent plasma from a recovered COVID -19 patient or 
anti-SARS -CoV -2 mA b is also not permitted during the study.   
Receipt of any vaccine is not permitted within 4 weeks after dosing. Receipt of any 
investigational or approved SARS -CoV -2 vaccine is permitted following Week 4. 
Patients should consult with the primary investigat or and their primary care physician on 
local guidelines for vaccine administration and guidance on the risk s associated with 
admi nistration  of a SARS -CoV -2 vaccine while on study.  
6.8.2.  Permitted Concomitant Medication  
All medication that the participant is receiving as local , established  standard of care  for 
acute  COVID -19 is permitted.  
Any concerns regarding the acceptability of potential treatments should be discussed with 
the medical monitor(s).  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 43 7. DISCONTINUATION OF STUDY  INTERVENTION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention  
A participant will be permanently discontinued from completion of drug infusion if they 
experience life -threatening, infusion -related reactions including severe allergic or 
hypersensitivity reactions or severe cytokine release syndrome.  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued, the participant will  
rema in in the study to be evaluated for  follow -up assessments . See the Schedule of 
Activities  in Section  1.3 for data to be collected at the time of discontinuation of study 
intervention and follow -up and for any further evaluations that need to be completed . 
7.1.1.  Temporary Discontinuation  
If a participant experiences a Grade 2 IRR, investigators will be instructed to pause the 
infusion. The infusion may su bsequently resume at a slower pace at the investigator’s 
discretion, and/or after symptomatic treatment (e.g. anti -histamines, IV  fluids).  
7.2. Participant Discontinuation /Withdrawal  from the Study  
• A participant may withdraw from the study at any time at his/he r own request , at the 
request of their LAR  (legally authorized representative) , or may be withdrawn at any 
time at the discretion of the investigator for safety, behavioral, or compliance reasons.  
This is expected to be uncommon.  
• At the time of withdrawal  from the study, if possible, an early withdrawal  (EW) visit 
should be conducted, as shown in the Schedule of Activities  (Section  1.3). 
Participants may be contacted by phone. See Schedule of Activities  for data to be 
collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
• If the participant withdraws consent or the LAR reques ts that the participant is 
withdrawn for disclosure of future information, the sponsor/designee may retain and 
continue to use any data collected before such a withdrawal of consent.  
• If the participant withdraws  from the study, he/she or the LAR may reques t 
destruction of any samples taken and not tested, and the investigator must document 
this in the site study records.  
7.3. Lost to Follow Up  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is u nable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a 
required study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible an d counsel the participant on the importance of maintaining the Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 44 assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study.  
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record.  
• If participants cannot be reached after 3 telephone calls at least 24 hours apart, their 
listed secondary contact person(s) or health care provider will be contacted.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are described in  
Section  10.1.9 .  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 45 8. STUDY ASSESSMENTS AN D PROCEDURES  
This section lists the parameters of each planned study assessment.  
• Study procedures and their timing are summarized in Section  1.3 (Schedule of 
Activities ).  
• Select f ollow -up visits as noted in the Schedule of Activities  are planned to be phone 
call from site to participants . Follow -up visits that include only blood collectio ns may 
be performed at the clinic or a s a home visit.   
• Protocol waivers or exemptions are not allowed .  
• Immediate safety concerns should be discussed with the medical monitor  immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
• Adherence to the study design requirements, including those specified in the Schedule 
of Activities , is essential and required for study conduct.  
• All screening eva luations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for scr eening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of ICF may be utilized for screening 
or baseline purposes provided the procedure met the protocol -specified criteria and 
was performed  within the time frame defined in the Schedule of Activities . 
• PK or ADA analysis results  that could unblind the study will not be reported to 
investigative sites or other blinded personnel until the study has been unblinded . 
• Repeat or unscheduled samples may be taken for safety reasons  or for technical issues 
with the samples . 
• Validated and secure electronic access will be granted to Clinical Research 
Associates to review the pa rticipants ’ electronic records to veri fy that the information 
in the records matches the information entered in the Electronic Data Capture ( EDC ) 
system.  If required, in the event of a Quality Assurance audit, auditor(s) may be 
granted access  to electronic records . 
− In cases where validated and  secure electronic access to the participant’s 
electronic records is not available, unredacted Source Documents (including ICF, 
Regulatory Documents and Source data) will be uploaded into a regulatory and 
data privacy -compliant cloud environment, generatin g certified copies of source 
documents (as per ICH/GCP guidelines) to be verified by the Clinical Research 
Associate against the information entered in the Electronic Data Capture (EDC). 
As per ICH/GCP guidelines, the Principal Investigator and site staff users remain 
in control of the Source Documents, only site personnel can upload or invalidate 
source data, while only Clinical Research Associates  (or auditors, as required)  
assigned to a given site can view the Source Documents remotely . Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 46 8.1. Screening Period  
Informed consent must be obtained before conducting any study procedures. Participant’s 
informed consent will be obtained via a validated and secure e -consent system  where 
available . Screening will be performed no more than 24 hours prior to randomization  and 
include  the assessments outlined in the Schedule of Activities  (Section  1.3).  
Screening visit and Day 1 visit may occur on the same day.  
8.1.1.  Medical History  
Relevant medical history within the last three years , as determined by the I nvestigator , 
should be reported . Details regarding illnesses and allergies, date(s) of onset, and whether 
condition (s) is currently ongoing will be collected for all participants and should be 
updated prior to dosing.  
8.1.2.  SARS -CoV -2 Diagnostic Testing  
Documentation of laboratory -confirmed SARS -CoV -2 infection via a validated 
diagnostic test  (e.g. RT -PCR  or antigen based t esting ) from any respiratory specimen 
collected ≤ 7 days prior to study entry  must be confirmed for eligibility . This can include 
tests conducted in a Clinical Laboratory Improvement Amendments (CLIA) certifi ed 
laboratory  or equivalent or from a validated CLIA -waived platform (e.g.  Ceph eid Gene 
Xpert Xpress  SARS -CoV -2 assay ).  
Participant s with a negative test prior to screening, who are tested  again  at screening and 
are positive for SARS -CoV -2 can be included as long as the participant has had 
symptoms ≤ 5 days.  
8.1.3.  Secondary Contact Information  
In order to minimize the potential for missing data related to the primary endpoint of 
mortality or need for hospitalization, sites should collect participant  contact information 
for two secondary contacts (e.g., caregiver, family member, friend). The s ite may also 
request health care provider contact information and medical care facilities the participant 
is likely to go to if they get sick.  
Contact informati on for secondary contacts or health care provider will not be recorded in 
any eCRF. Contact information should be reviewed and updated at each clinic visit, home 
visit, and  during  site phone call s.  
8.2. Efficacy  Assessments  
8.2.1.  Hospitalization and Death Data Collection  
A hospitalization event and the clinical care that is received during a hospitalization as 
well as death  are components of primary, secondary, and exploratory endpoints . Data 
from the hospitalization  and/or death should be captured in the electr onic data capture 
(EDC) system  including but not limited to:  
1. Serious Adverse Event (SAE) form  
2. Dates that the participant is hospitalized and discharged  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 47 3. Dates that the participant is admitted to an intensive care unit  
4. Ventilatory support  that the participant received  
5. Date, time , and cause of death  
8.2.2.  Active  Monitoring of COVID -19 Progression  Phone Call  
8.2.2.1.  Lead -In Phase  
During the Lead -In phase of the study, participants will be admitted to a study unit and 
monitored closely for 7 days after dos ing for adverse events , changes in laboratory 
parameters and progression (or improvement) in disease signs and symptoms. If they do 
not show signs and symptoms of progression after 7 days, they will be discharged from 
the study unit.  
During Week 2, the par ticipants will be called by the study site daily (except on in-clinic 
visit days) to monitor for progression of disease. This will include questions regarding 
serious or life -threatening conditions such as dyspnea at rest or severe dyspnea on 
exertion , hemoptysis, cyanosis, or mental status changes. If a participant exhibits any of 
these symptoms, the site will direct the participant to seek medical attention . In addition, 
any healthcare encounters or new concomitant medications will be recorded.  
8.2.2.2.  Expan sion Phase  
During the Expansion portion of the study, the participants will be called by the study site 
daily (except on in-clinic visit days) for 14 days post-infusion to monitor for progression 
of disease. This will include questions regarding serious or  life-threatening conditions 
such as dyspnea at rest or severe dyspnea on exertion, hemoptysis, cyanosis, or mental 
status changes. If a participant exhibits any of these symptoms, the site will direct the 
participant to seek medical attention.  In addition , any healthcare encounters or new 
concomitant medications will be recorded.  
8.2.3.  Phone Call for Subsequent COVID -19 Illness  
In order to monitor  participants fo r subsequent  COVID -19 illness after Day 29, 
participants will be called every 4 weeks through Week 20. This phone call will assess 
whether the participant was diagnosed again with COVID -19 and whether this illness 
resulted in any healthcare encounters. Any medications given as a result of this illness 
will also be recorded . 
8.2.4.  Participant Reported  Outcome As sessments  
All questionnaires are planned to be administered using an electronic device  where 
available . Details of the participant reported outcome assessment  analyses will be 
provided in the analysis plan. 
8.2.4.1.  FLU -PRO Plus Questionnaire  
In both the lead -in and expansion phase s, participants will complete self -reported  
presence and severity of COVI D-19 symptoms using a COVID -19 adapted FLU -PRO  
Plus questionnaire.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 48 The questionnaire  will be completed  where available,  once daily with a 24 -hour recall, 
from  Day 1 t hrough  Day 21, Day 29 , Week 8 and Week 12 as outlined in the Schedule of 
Activities ( Section  1.3). 
8.2.4.2.  Health -related Quality of Life (SF -12 Hybrid)  
In the expansion phase, t he SF-12 hybrid questionnaire  will be used to measure 
self-reported functional health and well -being  where available . Participants will complete 
the questionnaire with a 24 -hour recall on Day 1 , Day 15 , and  Day 29. Starting on Week 
8, participants will complete the questionnaire monthly through Week 24 as  outlined in 
the Schedule of Activities ( Section  1.3). 
8.2.4.3.  Work  Productivity and Activity Impairment (WPAI)  
The WPAI is a validated, patient -reported, quantitative assessment of absenteeism (work 
time missed), presenteeism (reduced on -the-job effectiveness), work productivity loss 
and activity impairment due to a spec ific health problem. In the expansion phase , where 
available participants will complete the 6 -item questionnaire via an elec tronic device  on 
Day 1 , Day 15 and Day 29 . Starting on Week 8, participants will complete the 
questionnaire monthly as outlined in the Schedule of Activities ( Section  1.3). 
To assess the impact of local shelter -in-place and/or lockdown policies, questions related 
to social distancing, ability to work on -site / remotely will be asked prior to the WPAI 
questionnaire.  
8.2.5.  Long COVID Assessment  
To monitor for subsequent development of long COVID during the EOS visit, 
participants will be asked a series of questions to evaluate a ra nge of symptoms after first 
being infected with the SARS -CoV -2. These questions will assess whether the participant 
experienced persistent symptoms since the COVID -19 diagnosis, type of symptoms, 
frequency, change over time, and impact on social functionin g. The questions can be 
asked and completed via phone call or during the in -clinic visit  (see Section 10.6). 
8.3. Safety Assessments  
Planned time points for all safety assessments are provided in the Schedule of Activities 
(Section  1.3). 
8.3.1.  Physical Examinations  
A co mplete physical examination  will be performed on Day 1 . For all other visits the 
physical examination will be symptom -directed  as outlined in the  Schedule of Activities . 
• A complete physical examination will include, at a minimum, assessments of the 
Skin, Cardiovascular, Respiratory, and Abdominal  systems.  
• Height and weight will also be measured and recorded  at Screening . Body mass index 
(BMI) will  be calculated f rom these measurements.  
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 49 8.3.2.  Vital Signs  
Lead -In Phase  
During dose administration, v ital signs will be monitored every 15 minutes over the 
1-hour IV infusion. Vital signs will also be monitored at 1, 2 and 6 hours  after infusion. 
After the first 6 hours after infusion, vital signs will be monitored every 8 hours  while the 
participant is in-clinic.   
Expansion Phase  
During dose administration, v ital signs will be monitored every 15 minutes over the 
1-hour IV infusion. Vital signs will also be monitored at 1 hour  and 2 hours after 
infusion.  
• Vital sign measurements will include blood pressure, pulse rate, temperature (oral 
preferred), respiratory rate,  and oxygen saturation.  
• Blood pressure and pulse measurements will be assessed while p articipant  is 
semi -supine  or sitting with a completely automated device. Manual techniques will be 
used only if an automated device is not available.  
• Blood pressure and p ulse measurements should be preceded by at least 5 minutes of 
rest for the participant in a quiet setting without distractions ( e.g., television, cell 
phones) . 
8.3.3.  Electrocardiograms  
Electrocardiogram will be  performed locally . Recording  should be reviewed on -site by 
the investigator .  
• For the lead -in phase,  12-lead ECG will be obtained as outlined in the Schedule of 
Activities  (see Section  1.3) using  an ECG machine that automatically calculate s the 
heart rate and measures PR, QRS, QT, and QTc intervals.  
• For the expansion phase, 12 -lead ECG will be obtained prior to dose administrati on 
on Day 1 . 
8.3.4.  Cardiac Monitoring  
Given the  potential for direct myocardial involvement by SARS -CoV -2, it is possible that 
ADE of disease could manifest as cardiac toxicity (Huang 2020 ). To monitor this, for 
participants who develop new or worsening cardiac symptoms, signs or ECG findings 
suggestive of an acute MI or cardiac failure , cardiology consultation will be 
recommended to guide further cardiac work up and assessment of potential c ardiac 
events . Event details should be captured in the appropriate EDC forms.  
8.3.5.  Virologic Measures  
Samples for virological analysis will be collected in accordance with  the laboratory 
manual and Schedule of Activities  (Section  1.3).  
• Nasopharyngeal swabs will be collected for SARS -CoV -2 RT -PCR  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 50 • Nasopharyngeal swab on Day 1 will include  respiratory viral panel  to asses 
coinfection  
• Blood samples will be collected for quantitative SARS -CoV -2 RT-PCR  
Samples may also be used for resistance surveillance analysis.  
8.3.6.  Clinical Safety Laboratory Assessments  
• See Section  10.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities  (Section  1.3) for the timing and frequency.  
• Laboratory assessments at Screening visit for the Lead -In phase and Expansion phase 
will be performed locally  at the clinical site . 
• To ensure timely safety management of the participants,  local laboratory assessments 
per sta ndard  of care at the clinical site  will be performed for the in -patient portion  of 
the Lead -In phase as outlined in the Schedule of Activities . 
• In the Lead -In phase only, urine will be collected on Day 1 (pre -dose) and Day 2 for 
analysis of albumin to crea tinine ratio conducted locally.  
• All protocol -required laboratory test performed centrally , as defined in  Section  10.2, 
must be conducted in accordance with the laboratory manual and Schedule of 
Activities  (Section  1.3) 
− The investigator must review the laboratory report, document this review, and 
record any clinically significant changes occurring during the study as an  AE. The 
laboratory reports must be filed with the source documents.  
− Abnormal laboratory  findings associated with the underlying disease  are not 
considered clinically significant , unless judged by the investigator to be more 
severe than expected for the participant ’s condition.  
− All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within 2 days  after the last dose of study 
intervention  should be repeated until the values return to normal or baseline or are 
no longer con sidered significantly abnormal by the investigator or medical 
monitor.  
− If clinically significant  values do not return to normal/baseline within a period of 
time judged reasonable by the investigator, the etiology should be identified and 
the sponsor notif ied. 
• If laboratory values from non -protocol specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by the investigator (e.g.,  SAE or AE or dose 
modifica tion), then the results must be recorded.  
8.3.7.  Pregnancy Testing  
• Refer to Section  5.1 Inclusion Criteria for pregnancy testing entry criteria.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 51 • Pregnancy tes ting (urine or serum as required by local regulations) should be 
conducted at Screening to confirm eligibility and at Week 24 or Early Withdrawal 
visit.  
• Additional serum or urine pregnancy tests may be performed, as determined 
necessary by the investigator  or required by local regulation, to establish the absence 
of pregnancy at any time during the participant’s participation in the study.  
8.4. Adverse Events  (AEs),  Serious Adverse Events  (SAEs) and 
Other Safety Reporting  
The definitions of adverse events (AE) or serious adverse events ( SAE s) can be found in 
Section  10.3. 
The definitions of unsolicited and solicited adverse events can be found in  Section  10.3. 
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative).  
Since hospitalization or death are SAEs and they are included in the primary endpoint, 
they will be collected and reported as SAEs as delineated in Section  8.4.1  below. Since it 
will not be poss ible to delineate in a single participant whether the hospitalization is 
directly related to COVID -19 complications or could be related to VIR -7831 causing 
more severe disease due to ADE, all hospitalizations regardless of cause will be included 
in the pri mary endpoint and will also be counted as serious adverse events (with the 
exception of elective treatment of a pre -existing condition that did not worsen from 
baseline as noted in Section  10.3). 
The investigator and any qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study intervention  or the 
study, or that caused the participant to discontinue the  study  (see Section  7). As noted in 
Section  8.2.1  data on hospitalization or death should additionally be recorded in the 
eCRF for all relevant sections.  
The method of record ing, evaluating, and assessing causality of A Es and SAEs and the 
procedures for completing and transmitting SAE reports are provided in  Section  10.3. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 52 8.4.1.  Time Period and Frequency for Collecting AE and SAE Information  
• All A Es will be collected through Week 12  post-dose. SAEs  will be collected from 
dose administration through  the Week 24 follow -up visit at the time points specified 
in the Schedule of Activities  (Section  1.3). However, any SAEs assessed as related to 
study participation (e.g., study intervention, protocol -mandated procedure, invasive 
tests or change in existing therapy) will be recorded from the t ime participant 
consents to participate in the study.  
• Medical occurrences that begin before the start of study intervention  but after 
obtaining informed consent will be recorded as Medical History/Current Medical 
Conditions not as AEs. 
• All SAE s will be re corded and reported to the sponsor or designee immediately and 
under no circumstance should this exceed 24 hours,  as indicated in Section  10.3. The 
investigator will submit any updated SAE data to the sponsor or designee within 
24 hours of it being available.  
• Investigators are not obligated to actively seek information on AEs or SAEs  after the 
conclusion of the study particip ation . However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the study, 
and he/she considers the event to be reasonably related to the study intervention  or 
study participation, the investiga tor must promptly notify the sponsor  or designee . Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 53 8.4.2.  Assessment of Severity  
Standard toxicity grading according to the  DAIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events , version 2.1 (July 2017) will be used to grade all A Es.  
8.4.3.  Method o f Detecting A Es and SAEs  
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence.  
8.4.4.  Follow -up of A Es and SAEs  
After the in itial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAE s and non -serious A Es of special 
interest (as defined in  Section  8.4.8 ), will be followed until the event is resolved, 
stabilized, otherwise  explained, or the participant is lost to follow -up (as defined in  
Section  7.3). Further information on follow -up procedures is given in  Section  10.3. 
8.4.5.  Regulatory Reporting Requirements for SAEs  
GlaxoSmithKline (GSK)  is acting on behalf of Vir for the purposes of global safety 
reporting for this study.  
• Prompt notification by the investigator to GSK  of an SAE is essential so that legal 
obligations and ethical respons ibilities towards the safety of participants and the 
safety of a study intervention  under clinical investigation are met.  
• GSK  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a stud y intervention  under clinical 
investigation. GSK  will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and investigators.  
• An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (e.g., summary or listing of SAEs) from GSK  will review 
and then file it along with the Investigator’s Brochure  and will notify the IRB/IEC, if  
appropriate according to local requirements.  
• Investigator safety reports must be prepared for suspected unexpected serious advers e 
reactions (SUSAR) according to local regulatory requirements and GSK policy and 
forwarded to investigators as necessary.  
8.4.6.  Pregnancy  
• Details of all pregnancies in  female participants will be collected after the start of 
study intervention  and until Week 24. 
• If a pregnancy is reported, the investigator will record pregnancy information on the 
appropriate form and submit it to  sponsor or designee  within 24 hours  of learning of 
the female  participant  pregnancy. While pregnancy itself is not considered to be an 
AE or SAE, any pregnancy complication or elective termination of a pregnancy for 
medical reasons will be reported as an AE  or SAE.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 54 • Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE s and will be reported 
as such . 
• The participant will be followed to determine the outcome of the pregnancy  and for 
up to 1 year after birth . The investigator will collect follow -up information on the 
participant  and the neonate /child  and the information will be forwarded to the sponsor  
or designee . 
• Any post -study pregnancy -related SAE considered reasonably rel ated to the study 
intervention by the investigator will be reported to the sponsor  or designee  as 
described in  Section  8.4.1 . While the investigator is  not obligated to actively seek this 
information in former study participants , he or she may learn of an SAE through 
spontaneous reporting.  
8.4.7.  Cardiovascular and Death Events  
For any cardiovascular events detailed in Section  10.3 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF will 
be required to be completed. These sections include questio ns regarding cardiovascular 
(including sudden cardiac death) and non -cardiovascular death.  
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular secti on of 
the CRF within one week of receipt of a CV Event data query prompting its completion.  
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within  one 
week of when the death is reported.  
8.4.8.  Adverse Events of Special Interest  
Adverse events of special interest  are defined in the study protocol as relevant known 
toxicities of other therapeutic  mAbs  or as a result of signals observed from previous 
studies in the nonclinical programs of VIR -7831 that will be monitored by the Sponsor 
either during or at the end of the study.  These will be updated during the course of the 
study based on accumulating safety data . 
AESI include:  
• Infusion -related reactions (IRR) i ncluding hypersensitivity reactions; reactions on 
same day as infusion  
• Immunogenicity related adverse drug reactions  
• Adverse events potentially related to a ntibody dependent enhancement of disease  
8.4.8.1.  Infusion -Related Reactions and Serious Hypersensitivity  
Pleae refer to local  or institutional g uidelines for monitoring relevant adverse events 
encompassing hypersensitivity, angioedema , anaphylaxis , acute anaphylactic shock and 
minor allergic episodes . Pre-medications will be permitted at the investigator’s discr etion 
and will be appropriately documented.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 55 8.4.8.2.  Immunogenicity  
Unwanted immunogenicity is an immune response by an organism against a therapeutic 
protein. This reaction leads to production of anti -drug-antibodies (ADA) which may 
inactivate the therapeutic effe cts of the treatment and, in rare cases, induce adverse 
events. This study will include participant follow -up for a period of 5 half -lives to assess 
for the development of ADA and potential impact s on safety , PK and/or efficacy.  
8.4.8.3.  Antibody Dependent Enhancem ent 
Antibody -dependent enhancement (ADE) of disease  theoretically can occur via one of 
three previously described mechanisms:  
1. By facilitat ing viral entry into host cells and enhanc ing viral replication  in these 
cells;  
2. By increasing viral fusion with target host cells, enhancing viral replication in 
these cells.  
3. By enhanc ing disease pathology from viral antigen -antibody related immune 
complex deposition or complement activation and immune cell recruitment in 
target organs ;  
The first two mechanisms are  hypothesized to occur at sub -neutralizing antibody 
concentrations  (Arvin 2020 ). This study will include participant follow -up for a period of 
5 half -lives to assess for the potential of enhanced disease in the context of waning 
VIR-7831 levels , which may manifest as an increased incidence of re -infection or 
increased severity of re -infections after recovery from initial illness . The third mechanism 
is hypothesized to occur at high levels of antigen (i .e., viral load) and antibody  potentially 
leading to immune complex deposition and complement activation in tissue sites of high 
viral replication. This  may manifest as acute deterioration temporally associated with 
VIR-7831 infusion or as increased severity or duration of illness in VIR-7831 -treated 
participants vs. p lacebo-treated participants . 
As described in  Section  2.3.1 , AEs potentially related to ADE of the disease will be 
reviewed by the IDMC to see if there is an imbalance in incidence or severity between 
the treatment groups.  
8.5. Pharmacokinetics  
Blood samples for serum PK will be collected as detailed in the Schedule of Activities  
(Section  1.3). Instructions for the collection and handling of biological samples will be 
provided by the sponsor or designee in the laboratory manual . 
• The actual date and time (24 -hour clock time) of each sample will be recorded.  
• Samples collected for analyses of VIR -7831  serum concentration may also be used to 
evaluate safety or efficacy aspects related to concerns arising during or after the 
study.  
• At visits during which whole blood samples are collected to obtain serum endpoints 
other than PK VIR -7831, one sample of sufficient volume can be used.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 56 • VIR-7831 serum concentration information that would unblind the study will not be 
reported to investigative sites or blinded personnel until the st udy has been unblinded.  
For the intensive sub -study in the Lead -In phase, pharmacokinetic parameters will be 
computed using standard noncompartmental methods. Parameters may include, but not be 
limited to C max, Clast, Tmax, Tlast, AUC inf, AUC last, %AUC exp, t1/2, λz, Vz, Vss, CL, and will 
be listed and summarized using descriptive statistics. Other parameters may be 
calculated, if deemed necessary. Definitions of PK parameters and methods for 
estimation will be included in the analysis plan. 
For the Expansio n Phase, serum concentrations may be combined with data from the 
Lead -In Phase in addition to other studies evaluating VIR -7831 for the purpose of 
population PK model development. Pharmacokinetic analyses may be conducted to 
explore exposure -response relat ionships between PK parameters and selected antiviral 
variables. These analyses may include graphical plots, tabular summaries, and various 
linear and/or nonlinear analyses. Details of the PK analyses will be provided in the 
analysis plan . 
8.6. Genetics  
A 2.5 mL blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the study. Sequencing of 
four genomic polymorphisms in FCGR2A, FCGR2B, FCGR3A, and IGHG1 loci will be 
performed on whole blood samples collected pre -dosing in all participants. Participation 
is optional. Participants who do not wish to participate in the genetic research may still 
participate in the study.  
In the event of DNA extraction failure, a replacement genetic b lood sample may be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
Samples will be collected in accordance with the laboratory manual and Schedule of 
Activities ( Section  1.3). 
8.7. Biomarkers  
Multiple immunology/biomarker samples will be collected from participants to evaluate 
host immune responses and exploratory biomarkers related to SARS -CoV -2 and/or 
VIR-7831, inclu ding genetic, cellular, transcriptomic, virologic,  and proteomic 
parameters.  
Whole blood samples will be collected for RNAseq to evaluate cellular populations and 
transcriptomes at early timepoints after treatment. This is a n optional test requiring 
consen t from patients. Serum will be collected throughout the course of the study to 
evaluate changes in serum biomarkers and cytokines at early timepoints following 
treatment (including but not limited to inflammatory cytokines and chemokines, such as 
IL-6, IFN -alpha, IL -1, IL -3, TNF -alpha, as available), as well as to evaluate the host 
antibody response to SARS -CoV -2 antigens over the duration of the study. In a 
sub-study, PBMC s will be collected to assess the frequency and function of SARS -CoV -
2 specific T cel ls. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 57 Samples will be collected in accordance with the laboratory manual  and Schedule of 
Activities ( Section  1.3). 
Sponsor may store samples for up to 15 years after the end of the study to achieve study 
objectives.  
8.7.1.  Resistance Analyses  
In order to monitor for resistance, resistance surveillance will be conducted for all 
participants who are randomized and dosed. Deep sequence analysis of the SARS -CoV -2 
spike gene will be attempted on baseline and post -baseline (from participants who do not 
experience a decline in viral load or who experience virologic rebound) nasopharyngeal  
samples to identify substitutions in the mAb  epitope or substitutions outside the epitope 
that arise during treatment. Virologic rebound will be defined as participants who 
experience an increase of >1 log 10 copies/mL in viral load for 2 consecutive visits, or 
viral load becomes quantifiable for 2 c onsecutive visits after having been below the limit 
of quantification. For identified substitutions that qualify for phenotypic analysis, in vitro 
phenotypic analysis of the antiviral activity of VIR -7831 using a SARS -CoV -2 spike 
pseudovirus system will be  attempted and analysed for reduced susceptibility to VIR -
7831.  
8.8. Immunogenicity Assessments  
Antibodies to VIR -7831 will be evaluated in serum samples collected from all 
participants according to the Schedule of Activities  (Section  1.3). Additionally, serum 
samples should also be collected at the final visit from participants who discontinued 
study intervention or were withdrawn from the study. These samp les will be tested by the 
sponsor or designee.  
Serum samples will be screened for antibodies binding to VIR -7831 and the titer of 
confirmed positive samples will be reported. Other analyses may be performed to verify 
the stability of antibodies to VIR -7831  and/or further characterize the immunogenicity of 
VIR-7831.  
The detection and characterization of antibodies to VIR -7831 will be performed using a 
validated assay method by or under the supervision of the sponsor or designee. All 
samples collected for detection of antibodies to study intervention will also be evaluated 
for VIR -7831 serum concentration to enable interpretation of the antibody data. 
Antibodies may be further characterized and/or evaluated for their ability to neutralize the 
activity of th e study intervention(s). Samples may be stored for a maximum of 15 years 
(or according to local regulations) following the last participant’s last visit for the study at 
a facility selected by the sponsor/designee to enable analysis of immune responses to 
VIR-7831  as described . 
Samples will be collected in accordance with the laboratory manual and Schedule of 
Activities ( Section  1.3). Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 58 9. STATISTICAL CONSIDER ATIONS  
9.1. Statistical Hypotheses  
The primary objective of this study is to evaluate the efficacy or VIR -7831 versus 
placebo in preventing the progression of COVID -19. 
The pr imary endpoint is proportion of participants who  have  progression of COVID -19 
through Day 29 as defined by hospitalization > 24 hours for acute management of illness 
or death .  
If we denote the proportion of participants with progression of COVID -19 in the  
VIR-7831 a rm as P A, and the proportion of participants with progression of COVID -19 in 
the placebo arm as P B, the following null and alternative hypothesis for superiority is as 
follows:  
H0: P A = PB  
H1: P A ≠ PB 
9.2. Sample Size Determination  
VIR-7831 and plac ebo will be randomized  in a 1:1 ratio.  
The study will utilize a group sequential design with two interim analyses to asses both 
futility due to lack of efficacy and overwhelming efficacy. A Lan -DeMets alpha -spending 
function to control the type I error will be used, using a Pocock analogue rule  for futility 
and a Hwang -Shih-DeCani ( with parameter γ = 1) analogue  for efficacy  [Hwang  1990 ]. 
The expected sample size is 680 participants per arm  No sample size re-estimation  is 
planned.  
Approximately 1360  (680 per arm) participants will be randomly assigned to study 
intervention . A total sample size of 1360  will provide approximately 90% power to detect 
a 37.5% relative efficacy  in reducing progression of COVID -19 through Day  29 at the 
overall two -sided 5% sign ificance level with assumed progression of COVID -19 rates of 
16% in the placebo arm and 10% in the VIR-7831 arm , respectively . The minimal 
detectable efficacy  for this design at the final efficacy analysis is approximately 25% if 
disease progression rates is 16% in the placebo arm . Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 59 9.3. Analysis Sets  
For the purposes of analysis, the following analysis sets are defined:  
Participant Analysis Set  Description  
Intent -to-Treat  All participants who were randomized according to the 
intervention they were randomized to. This will be the primary 
analysis set.  
Safety  All randomized participants who are exposed to study 
intervention. Participants will be analyzed according to the 
intervention they actually received.  
Per-Protocol  All participants in the ITT analysis set  for whom there were no 
major protocol deviations that impact the primary analyses.  
Data should be reported according to the intervention a 
participate was randomized to . 
Specific details of major protocol deviations that would exclude 
participants from the PP analysis will be defined in the analysis 
plan 
Pharmacokinetic  All participants in the Safety analysis set who had at least 1 
non-missing PK assessment (Non -quantifiable [NQ] values will 
be considered as non -missing values)  
Virology  All participants who were randomized according to the 
intervention they were randomized to and with a central lab 
confirmed  quan titative nasopharyngeal  swab at Day 1. This will 
be the primary analysis set for virology.  
 
Defined Analysis Data Sets  Description  
Analysis set for all efficacy 
estimands  All randomized participants. For participants who discontinue 
study intervention and/or receive rescue therapy, all post 
discontinuation or post rescue observations will be included  in 
the analysis set.  
Analysis set for all safety 
estimands  All randomized participants . For participants who discontinue 
study intervention and/or receive rescue therapy, all post 
discontinuation or post rescue observations will be included in 
the analysis set . 
9.4. Statistical Analyses  
The statistical analysis plan will be finalized  prior to unblinding  for the first IDMC  and it 
will include a more technical and detailed description of the statistical analyses described 
in this section . This section is a summary of the planned statistical analyses of the most 
important endpoints including primary and key secondary endpoints.  
Any change to the data analysis methods described in the protocol will require an 
amendment only if it changes a principal feature of the protocol. Any other change to the 
data analysis methods described in the protocol and the justification for making the Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 60 change will be described in the statistical analysis plan.  Additional exploratory analyses 
of the data will be c onducted as deemed appropriate.  
9.4.1.  General Considerations  
In the case of a difference between the stratification assigned at the time of randomization 
and the data collected in the eCRF, the analyses will be performed based on the 
calculated stratum at random ization.  
Confidence intervals will use the 95% levels unless otherwise specified.  
9.4.2.  Primary  Endpoint(s)  
The primary endpoint will be proportion of participants who have progression of 
COVID -19 as defined by hospitalization > 24 hours for acute management of  illness or 
death through Day 29 . 
The primary analysis will be the comparison of prog ression rate  within 29 days between 
VIR-7831  and placebo using generalized linear model (GLM) with log binomial link, 
adjusted for treatment (VIR -7831 vs. placebo), durati on of symptoms ( ≤3 days vs. 
4-5 days) , age ( ≤70 vs. >70 years old) and gender (female vs. male ) to test for 
superiority of  VIR-7831 versus placebo.  If the GLM does not converge then it will be 
approximated by a Poisson regression model with a robust sandwich estimator, adjusted 
for the same covariates of GLM. If the P -value from the GLM  (or from Poisson 
regression model if GLM does not converge)  is less than the  adjusted significance 
level 02446, a statistically significant advantage in favor  of VIR -7831 will be declared. 
Relative risk  of VIR -7831 versus  placebo and its 95% confidence interval (CI)  will be 
estimated . At each of the interim and final efficacy analysis,  appropriate CI  based on 
the adjusted significance level will also be provided.   
Possible intercurrent events are withdrawal of consent and lost -to-follow -up on or before 
Day 29. The strategy for analysis for these intercurrent events, will be to use the 
treatment policy strategy, with data analyzed as collected. It is expected missing data will 
be minimal and most will be lost to follow up data after discharge and this along with 
intermittent data will be imputed using multiple imputation under th e missing at random 
assumption. Every effort will be made to reduce missing data  (refer to  Section  7) . 
Supplemental estimand strategies and missing data sensitivities will be performed and 
further details will be provided in the analysis plan.  
9.4.3.  Secondary E ndpoint(s)  
Full details of all analysis methods for the secondary endpoints will be provided in the 
analysis plan.  
9.4.4.  Exploratory E ndpoint(s)  
Full details of all analysis methods for the exploratory endpoints will be provided in the 
analysis plan.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 61 9.4.5.  Safety Analys is 
For safety data, no formal  hypotheses will be tested. Occurrence of AEs, non-COVID -19-
related AEs,  SAEs,  non-COVID  19 relate SAEs,  and AESIs, including laboratory tests, 
vital signs, and ECG  abnormalitie s will be displayed in the form of listings, frequencies, 
summary statistics, graphs, and statistical analyses where appropriate. Interpretation will 
be aided by clinical expertise.   
As noted in Section 8.4, since it will not be possible to delineate in a s ingle participant 
whether the hospitalization is directly related to COVID -19 complications or could be 
related to VIR -7831 causing more severe disease due to ADE, all hospitalizations 
regardless of cause will be included in the primary endpoint and will a lso be counted as 
serious adverse events . To inform on the number and nature of non -COVID -19 adverse 
events and serious adverse events,  additional  safety  analyses  will be performed  in which 
select, pre -specified terms consistent with known progression of C OVID -19 disease will  
be excluded . Details of these  and all analyses , including example outputs, will be 
documented in the analysis plan.  
9.4.6.  Other Analys is 
Full details of all analysis methods of immunogenicity and population pharmacokinetics 
will be provided in the analysis plan.  
9.5. Interim Analys is 
Interim analysis will be used to assess safety (due to harm), futility due to lack of efficacy 
and efficacy . A non -binding statistical framework for evaluating number of events of 
interest will be provided to aide the  IDMC  to make recommendations based  upon 
the totality of available safety data from the  study.  
Full details of timing of analyses and all stopping criteria will be given in the IDMC 
charter.  
Interim analyses to assess efficacy and futility are planned when  approximately 41% and 
64% of the required number of participants  have reached Day 29  visit. The analysis of the 
primary endpoint at the interim analyses will be the same as that described for the 
primary endpoint. Group sequential techniques will be used to adjust stopping boundaries 
to reflect the actual number of partici pants  with available data for primary endpoint at the 
time of each interim analysis. The full decision criteria for the futility due to lack of 
efficacy and efficacy rules along with addi tional information to be presented to the IDMC 
will be defined in the IDMC charter and associated documents, as well as the analysis 
plan.  
The Joint Safety Review Team (JSRT) comprising individuals from Vir and GSK will 
review blinded safety data at regular intervals throughout the conduct of the study and 
determine if a safety concern based on instream blinded data review needs to be escalated 
to the IDMC. Details of the JSRT process is recorded in relevant SRT documents.  
Following all participants c ompleting the final follow -up visit at Week 24, a final safety 
analysis will be performed . Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 62 10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) Internation al Ethical Guidelines  
− Applicable ICH Good Clinical Practice (GCP) Guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB/IEC by the investigator  and reviewed 
and approved by the IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC  
− Notifying the IRB/IEC of SAE or other s ignificant safety findings as required by 
IRB/IEC procedures  
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC , EU Clinical Trials 
Directive 2001/20/EC or Regulation (EU) No. 53 6/2014 (if applicable), and all 
other applicable local regulations  
10.1.2.  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor  or designee  with sufficient, 
accurate financial information as requested to allow the sponsor /designee  to submit 
complete and accurate financial certification or disclosure statements to the appropriate 
regulatory authorities. Investigators  and sub -investigators  are responsible for providing 
information on financial interests during the course of the study and for 1 year after 
completion of the study.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 63 10.1.3.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant  or their legally authorized representative  and answer all questions 
regarding the study.  
• Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representative  will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability and Accountability Act (HIPAA) requirements, where 
applicable, and the IRB/IEC or study cente r.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign t he ICF.  
• Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
• A signed copy of the ICF(s) must be provided to the participant  or their legally 
authorized representative.  
Vir (alone or working  with others) may use the participant’s coded study data and 
samples and other information to carry out this study; understand the results of this study; 
learn more about  VIR-7831 or about the study disease; fulfill legal and regulatory 
obligations, includ ing reporting safety information about VIR -7831, this study, and the 
results of this study to regulatory authorities; provide information about the safety and 
use of VIR -7831 to investigators and institutions that plan to administer VIR -7831 to 
patients; publish the results of these research efforts; work with government agencies or 
insurers to have VIR-7831  approved for medical use or approved for payment coverage.  
10.1.4.  Data Protection  
• Participants will be assigned a unique identifier by the sponsor /designee . Any 
participant records or datasets that are transferred to the sponsor /designee  will contain 
the identifier only; participant names or any information which would make the 
participant identifiable will not be transferred.  
• The participant must be informed  that his/her personal study -related data will be used 
by the sponsor /designee  in accordance with local data protection law. The level of 
disclosure must also be explained to the participant , who will be required to give 
consent for their data to be used a s described in the informed consent .  
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
sponsor /designee , by appropriate IRB/IEC members, and by inspectors from 
regulatory authorities.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 64 10.1.5.  Committees Structure  
Independent Data Monitoring Committee (IDMC)  
An IDMC will actively monitor interim unblinded safety (Lead -In Phase) and interim 
unblinded safety and efficacy data (Expansion Phase) to make rec ommendations to Vir as 
detailed in the IDMC Charter. The IDMC members will include at least 2  physicians with 
relevant medical training and one statistician. Details regarding the IDMC process will be 
available in relevant IDMC documents.  
Details of the st ructure and function of the IDMC, and analysis plan for IDMC reviews 
are outlined in the IDMC Charter, which is available upon request.  
Joint Safety Review Team  
The Joint Safety Review Team (JSRT) comprised of individuals from Vir and GSK will 
review blin ded safety data at regular intervals throughout the conduct of the study and 
determine if a safety concern based on instream blinded data review needs to be escalated 
to the IDMC. Details of the JSRT process is recorded in relevant SRT documents.  
10.1.6.  Dissemina tion of Clinical Study Data  
• Where required by applicable regulatory requirements, an investigator signatory will 
be identified for the approval of the clinical study report. The investigator will be 
provided reasonable access to statistical tables, figures , and relevant reports and will 
have the opportunity to review the complete study results at a sponsor  site or other 
mutually -agreeable location.  
• Sponsor or designee  will also provide all investigator s who participated  in the study  
with a summary of the study results  and will tell the investigators what treatment their 
study participant s received. The investigator (s) is/are encouraged to share the 
summary results with the study participan ts, as appropriate.  
• Under the framework of the SHARE  initiative, the sponsor  intends to make 
anonymized participant -level data from this trial available to external researchers for 
scientific analyses or to conduct research that can help advance medical science or 
improve patient care. This helps ensure the  data provided by trial participants are used 
to maximum effect in the creation of knowledge and understanding. Requests for 
access may be made through www.clinicalstudydatarequest.com . 
• Sponsor or its designee  will provide the investigator with the randomization codes for 
their site only after completion of the full statistical analysis.  
• The procedures and timing for public disclosure of the protocol and results summary 
and for development of a manuscr ipt for publication for this study will be in 
accordance with GSK Policy.  
• A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 65 10.1.7.  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF s unless transmitted to the sponsor or designee electronically ( e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate and 
correct by phys ically or electronically signing the CRF.  
• Guidance on completion of CRFs will be provided in  the data entry guidelines.  
• Quality Toleranc e limits (QTLs) will be pre -defined in the Integrated Quality Risk 
Management Plan  to identify systematic issues that can impact participant safety 
and/or reliability of study results. These pre -defined parameters will be monitored 
during and at the end of the study , and all deviatio ns from the QTLs and remedial 
actions taken will be su mmarized in the clinical study report.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy  including de finition of study critical data items 
and processes  (e.g., risk -based initiatives in operations and quality such as Risk 
Management and Mitigation Strategies and Analytical Risk -Based Monitoring), 
methods, responsibilities and requirements, including handl ing of noncompliance 
issues and monitoring techniques (central, remote, or on -site monitoring) are provided 
in the  Monitoring Plan.  
• The sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
• The sp onsor assumes accountability for actions delegated to other individuals  
(e.g., Contract Research Organizations).  
• Records and documents, including signed ICF s, pertaining to the conduct of this 
study must be retained by the investigator for 25 years from t he issue of the final 
Clinical Study Report (CSR)/equivalent summary  unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed 
during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party without written notification to the 
sponsor.  
• As hospitalization and mortality are both primary study endpoints and serious adverse 
events, instream data cleaning including updating and reconciliat ion of hospitalization 
events between the safety dataset and efficacy dataset will be performed throughout 
the study duration and any changes or updates to the SAEs of hospitalization or 
mortality will be reflected in the efficacy dataset.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 66 10.1.8.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the  printed  CRF s or entered in the electronic eCRF s that are 
transcribed from source documents must be consistent with the source documents or 
the discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the study. Also, current medica l 
records must be available.  
• Definition of what constitutes source data and its origin can be found in [ Source Data 
Acknowledgment ]. 
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
• Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and  that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
First Act of Recruitment  
The study start date is th e date on which the clinical study will be open for recruitment of 
participants.  
Study/Site Termination  
Vir reserves the right to close a study site or terminate the study at any time for any 
reason at the sole discretion of Vir. Study sites will be closed  upon study completion. A 
study site is considered closed when all required documents and study supplies have been 
collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include 
but are not limited to:  
For study termination:  
• Discontinuation of further study  intervention development  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 67 • Inadequate or no recruitment of participants (evaluated after a reasonable amount of 
time) by the investigator  
• If the study is prematurely terminated or suspended, the sponsor shall promptly 
inform the investigators, the IECs/IRBs, the regulatory authorities, and any contract 
research organization(s) used in the study of the reason for termination or suspension, 
as specified by the applicable regulatory requirements. The investigator shall 
promptly inform  the participan t(s) and should assure appropriate participant therapy 
and/or follow -up 
10.1.10.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts  or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary information 
and to provide comments.   
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and e thical practice, the sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement.  
• Authorship will be determined b y mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  
10.2. Appendix 2: Clinical Laboratory Tests  
The tests detailed in Table  4 will be performed by either the central laboratory or the site 
local laboratory.   
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 68 Table  4: Protocol -Required Safety Laboratory Tests  
Laboratory 
Assessments  Parameters  
 Hematocrit  ABO typing2 Urine albumin to creatinine ratio3 
Hematology  Platelet Count   RBC Indices:  
MCV  
MCH  
%Reticulocytes  WBC count with Differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC Count  
Hemoglobin  
Clinical 
Chemistry  BUN  Potassium  Aspartate 
Aminotransferase  
(AST)/  Serum 
Glutamic -Oxaloacetic 
Transaminase  (SGOT)  Total and direct 
bilirubin  
 Creatinine6 Sodium  Alanine 
Aminotransferase  
 (ALT)/  Serum 
Glutamic -Pyruvic 
Transaminase  (SGPT)  Total Protein  
Glucose (non-
fasting ) Calcium  Alkaline phosphatase  Gamma -glutamyl 
transferase (GGT)  
 Carbon 
dioxide/b icarbonate  Chloride  Lactate dehydrogenase 
(LDH)  Albumin  
 Amylase  Lipase    
Coagulation 
parameters  International 
Normalized Ratio 
(INR) time  Prothrombin 
time (PT)  Partial thromboplastin 
time (PTT) / Activated 
PTT (aPTT)   
Pregnancy 
testing  Highly sensitive (Serum/plasma or urine)  human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women of childbearing potential)  
Inflammatory 
Markers1 C-reactive protein1, 5 Ferritin1, 5 IL-61, 5  
Respiratory 
Pathogens4 Respiratory viral 
panel  by PCR4    
1 Parameters  not included in local lab oratory assessments performed at Screening visit  
2 Screening  visit only to be performed locally  
3Lead -In phase only: Day 1 (pre -dose) and Day 2 to be performed locally .  
4 Day 1 only and performed by central laboratory  
5 Day 1, 15 and 29 visits only and performed by central laboratory  
6 Repeat if above the normal range  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 69 10.3. Appendix 3: AEs and SAEs : Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
a. An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study intervention, whether or not considered related to the 
study intervention.  
NOTE:  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory fin ding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study intervention.  
 
Definition of Unsolicited and Solicited AE  
b. An unsolicited adverse event is an adverse event that was not solicited using a Participant 
Diary and that is communicated by a participant  who has signed the informed consent. 
Unsolicited AEs include serious and non -serious AEs.  
c. Potential unsolicited AEs may be medically attended (i.e., symptoms or illnesses requiring 
a hospitali zation, or emergency room visit, or visit to/by a health care provider). The 
participants will be instructed to contact the site as soon as possible to report medically 
attended event(s), as well as any events that, though not medically attended, are of 
participant  concern.  Detaile d information about reported unsolicited AEs will be collected 
by qualified site personnel and documented in the participant’s records.  
d. Unsolicited AEs that are not medically attended nor perceived as a concern by participant 
will be collected during inter view with the participants and by review of available medical 
records at the next visit.  
e. Solicited AEs are predefined local at the infusion  site and systemic events for which the 
participant is specifically questioned, and which are noted by the participant in their diary.  
 
Events Meeting  the AE Definition  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after  study intervention administration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected  overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of seq uelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack o f efficacy will 
be reported as AE or SAE if they fulfill the definition of an AE or SAE.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 70 Events Meeting  the AE Definition  
• Clinically significant changes in laboratory assessments.  
 
Events NOT  Meeting the AE Definition  
1. Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
2. The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
3. Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
4. Situations in which an untoward med ical occurrence did not occur (social and/or 
convenience admission to a hospital).  
5. Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
 
10.3.2.  Definition of SAE  
An SAE is defined as any serious adverse event  that, at any dose:  
1) Results in death  
2) Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
3) Requires inpatient hospitalization or prolongation of existing hospitalization  
Appendix  A. In general, hospitalization signifies that the participant has been 
admitted (usually involving at least an overnight stay) at the hospital or 
emergency ward for observation and/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting. 
Complications that occur during hospitalization are AE. I f a 
complication prolongs hospitalization or fulfills any other serious 
criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be 
considered serious.  
Appendix  B. Hospitalization for elective treatment of a pre -existing condition that did 
not worsen from baseline is not considered an AE.  
4) Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 71 An SAE is defined as any serious adverse event  that, at any dose:  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( e.g. sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
5) Is a congenital anomaly/birth defect  
6) Other medically significant situations:  
• Possible Hy’s Law case: ALT≥3xULN AND total bilirubin ≥2xULN (>35% direct 
bilirubin) or international normalized ratio (INR) >1.5 must be reported as SAE  
• Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as significant 
medical events that may jeopardize the participant or may req uire medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
− Examples of such events include invasive or malignant cancers, intensive 
treatment for allergic br onchospasm, blood dyscrasias , convulsions, or 
development of intervention dependency or intervention abuse.  
 
10.3.3.  Definition of Cardiovascular Events  
Cardiovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
a. Myocardial infarction/unstable angina  
b. Congestive heart failure  
c. Arrhythmias  
d. Valvulopathy  
e. Pulmonary hypertension  
f. Cerebrovascular events/stroke and transient ischemic attack  
g. Peripheral arterial thromboembolism  
h. Deep v enous thrombosis/pulmonary embolism  
i. Revascularization  
 
10.3.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Recording  
a. When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation ( e.g. hospital progress notes, laboratory, and diagnostics reports) 
related to the event.  
b. The investigator will then record all relevant AE/SAE information.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 72 AE and SAE Recording  
c. It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to sponsor  in lieu of completion of the required form . 
d. There may be instances when copies of medical records for certain cases are 
requested by GSK  Pharma Safety staff . In this case, all participant identifiers, with 
the exception of the participant number, will be redacted on the copies of the 
medical records before submission.  
e. The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
• The investigator will make an assessment of intensity for each AE and SAE 
reported during the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by the participant, causing minim al 
discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utilized for 
rating the intensity of an event; and both AE and SAE can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys th at there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), c oncomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Infor mation, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred  and the investigator has minimal 
information to include in the initial report to sponsor . However, it is very important that 
the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to sponsor . 
• The investigator may change his/her opinion of causality in light of follow -up information 
and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 73  
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK to 
elucidate the nature and/or causality of the AE or  SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide sponsor  with a copy of any post -mortem findings 
including histopathology.  
• New or updated information will be recorded in the originally submitted documents . 
• The investigator will submit any updated SAE data to GSK within 24 hours of receipt of 
the information.  
10.3.5.  Reporting of SAE to GSK  
SAE Reporting to GSK via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to GSK will be the electronic data collection 
tool. 
• If the electronic system is  unavailable, then the site will use the paper SAE data collection 
tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• The investigator or medically -quali fied sub -investigator must show evidence within the 
eCRF (e.g., check review box, signature, etc.) of review and verification of the relationship 
of each SAE to IP/study participation (causality) within 72 hours of SAE entry into the 
eCRF.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see next section) or to 
the SAE coordinator by telephone.  
 
SAE Reporting to GSK via Paper Data Collection Tool  
• Facsimile transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the SAE coordinator.  
• In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy  of the SAE data collection tool sent by overnight mail or courier 
service.  
• Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE data collection tool  within the designated reporting time frames.  
 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 74 10.3.6.  Expedited Reporting to Health Authorities, Investigators and Ethics 
Committees  
Expedited Reporting  
The Sponsor will promptly evaluate all serious adverse events and non -serious adverse  
events to identify and expeditiously communicate new safety findings t o investigators, IRBs, 
ECs, and health authorities based on applicable legislation.  
 
To determine reporting requirements for single adverse event cases, the Sponsor will  
assess the expectedness of these events using the VIR -7831 Investigator’s  Brochure .  
10.4. Appendix  4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions:  
Woman of Childbearing Potential (WOCBP)  
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming post -menopausal unless permanently 
sterile (see below)  
Notes:  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
− A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal st ate in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation with more than one FSH measurement  
is required.  
− Females on HRT and whose menopausal status is in doubt wi ll be required to use 
one of the non -estrogen hormonal highly effective contraception methods if they 
wish to continue their HRT during the study. Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.  
• Permanent sterilization methods (for the purpose of this study) include:  
− Documented hysterectomy  
− Documented bilateral salpingectomy  
− Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than th e 
above,  (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 75 If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirme d before first dose of study intervention, additional evaluation should 
be considered.  
Woman of Nonchildbearing Potential (WONCBP)  
Women in the following categories are considered WONCBP:  
1. Premenopausal female with permanent infertility due to one of the fo llowing (for 
the purpose of this study):  
a. Documented hysterectomy  
b. Documented bilateral salpingectomy  
c. Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above,  (e.g., Mullerian agenes is, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry.  
Note : Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical histo ry interview.  
2. Postmenopausal female  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state  in women not using hormonal contraception 
or hormonal replacement therapy (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with more than one FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt must d iscontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 76 10.4.2.  Contraception Guidance:  
CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methods That Have Low User Dependency Failure rate of <1% per year 
when used c onsistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or  due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole 
sexual partner of the woman of childbearing potential and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participant can come from the site 
personnel’s review of the participant’s medical records, medical examination, or medica l 
history interview.)  
Highly Effective Methods That Are User Dependent Failure rate of <1% per year when 
used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation  
• oral 
• intravaginal  
• transdermal  
• injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulation  
• oral 
• injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual  intercourse during the entire period of risk associated with the study 
intervention. The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 77 10.5. Appendix  5: Genetics  
10.5.1.  USE/ANALYSIS OF DNA  
• Genetic variation may impact a participant’s response to study intervention , 
susceptibility, severity and progression of disease. Variable response to study 
intervention  may be due to genetic determinants that impact drug abso rption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analys is. 
• DNA samples will be used for research related to VIR-7831 mechanism of action in 
SARS -CoV -2 and related diseases. They may also be used to develop tests/assays 
(including diagnostic tests) related to VIR-7831  and related mAb therapeutics for 
SARS -CoV -2 and related diseases.  Genetic research may consist of the analysis of 
one or more candidate genes or the analysis of genetic markers throughout the 
genome . 
• DNA samples will be analyzed for  genomic polymorphisms in FCGR2A, FCGR2B, 
FCGR3A, and IGHG1 loci.   
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to VIR-7831  or study interventions of this class. The results 
of genetic analyses may be reported in the clinical study report or in a separate stud y 
summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on VIR-7831  (or study interventions of 
this class) or SARS -CoV -2 continues but no longer than 15 years after the last 
participant  last visit or other period as per local requirements.  
 
  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 78 10.6. Appendix 6: Long COVID Questionnaire  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright laws 
and therefore have been excluded.
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 79 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party 
copyright laws and therefore have been excluded.
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 80 Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third party copyright 
laws and therefore have been excluded.
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 81 11. REFERENCES  
A, Poon JL, Powers JH 3rd, Leidy NK, Yu R, Memoli MJ. Using the Influenza Patient -
reported Outcome (FLU -PRO) Diary to Evaluate Symptoms of Influenza Viral Infection 
in a Healthy Human Challenge Model. BMC Infect Dis. 2018 Jul 28;18(1):353. doi: 
10.1186/s12879 -018-3220 -8. 
Ali SO, Takas T, Nyborg A, Shoemaker K, Kallewaard NL, Chiong R, Dubovsky F, 
Mallory RM. Evaluation of MEDI8852, an Anti -Influenza A Monoclonal Antibody, in 
Treating Acute Uncomplicated Influenza. Antimicrob Agents Chemother. 2018 Oct 
24;62(11). pii: e00694 -18. doi: 10.112 8/AAC.00694 -18. Print 2018 Nov. PubMed PMID: 
30150460; PubMed Central PMCID: PMC6201130.  
Arvin AM, Fink K, Schmid MA, Cathcart A, Spreadfico R, Havenar -Daughton C, 
Lanzavecchia A, Corti D, Virgin HW. A perspective on potential antibody -dependent 
enhancemen t of SARS -CoV -2. Nature. https://doi.org/10.1038/s41586 -020-2538 -8 
(2020).  
Baxter LT, Zhu H, MackensenDG, Jain RK. Physiologically based pharmacokinetic 
model for specific and nonspecific monoclonal antibodies and fragments in normal 
tissues and human tumo r xenografts in nude mice. Cancer Res. 1994 Mar 15; 54(6): 
1517 –1528.  
Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, Ellington S, Gierke R, 
Hall A, MacNeil J, Patel P, Peacock G, Pilishvili T, Razzaghi H, Reed N, Ritchey M, 
Sauber -Schatz E. Severe  Outcomes Among Patients with Coronavirus Disease 2019 
(COVID -19) — United States, February 12 –March 16, 2020. MMWR Morb Mortal 
Wkly Rep 2020;69:343 -346. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e2.  
Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS -CoV -2 
infections: practical considerations and management strategy for intensivists. Intensive 
Care Med. 2020 Apr;46(4):579 -582. doi: 10.1007/s00134 -020-05967 -x. Epub 2020 Feb 
26. PubMed PMID: 32103284; PubMed Central PMCID: PMC7079839.  
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang 
T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q 
BMJ. 2020;368:m1091. Epub 2020 Mar 26. PMID 32217556 REFS: MMWR, March 18, 
2020 Garg et al, MMWR ~160 ho sp patients  
Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics 
of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res.1986 
Aug;46(8):3969 -78. 
Datta -Mannan A. Mechanisms Influencing the Pharmacokinetics and Disposition of 
Monoclonal Antibodies and Peptides. Drug Metab Dispos. 2019 Oct;47(10):1100 -1110.  
Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human 
pharmacokinetics of therapeutic antibodies from nonclinical data: what have we l earned? 
MAbs. 2011 Jan -Feb;3(1):61 -6. doi: 10.4161/mabs.3.1.13799. Epub 2011 Jan 1. PMID: 
20962582; PMCID: PMC3038012.  
FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID -19 
Pandemic (updated 14 May 2020). https://www.fda.gov/me dia/136238/download, 2020.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 82 Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, Bhatia S, 
Boonyasiri A, Cucunuba Perez Z, Cuomo -Dannenburg G, Dighe A, Dorigatti I, Fu H, 
Gaythorpe K, Green W, Hamlet A, Hinsley W, Okell L, Van Elsland S, T hompson H, 
Verity R, Volz E, Wang H, Wang Y, Walker P, Winskill P, Whittaker C, Donnelly C, 
Riley S, Ghani A. Impact of non -pharmaceutical interventions (NPIs) to reduce COVID - 
19 mortality and healthcare demand. Imperial College COVID -19 Response Team, 16  
March 2020. doi: https://doi.org/10.25561/77482.  
Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients 
hospitalized with laboratory -confirmed coronavirus disease 2019 - COVID -NET, 14 
states, March 1 -30, 2020. MMWR Morb Mo rtal Wkly Rep. 2020;69(15):458 -464. 
https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm  
Guan WJ, Ni ZY, Hu Y, et al. Characteristics of coronavirus disease 2019 in China. N 
Engl J Med. 2020. https://www.nejm.org/doi/full/10.1056/NEJMoa2002032  
Hamming I, Ti mens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution 
of ACE2 protein, the functional receptor for SARS coronavirus. A first step in 
understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631 -7. doi: 
10.1002/path.1570. PMID: 15141377; PMCID: PMC7167720.  
Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, Jeeninga R, Smits S, 
Trevejo J, Shriver Z, Oldach D. Safety and efficacy of monoclonal antibody VIS410 in 
adults with uncomplicated influenza A infection: Results from a rando mized, double -
blind, phase -2, placebo -controlled study. EBioMedicine. 2019 Feb;40:574 -582. doi: 
10.1016/j.ebiom.2018.12.051. Epub 2019 Jan 9. PubMed PMID: 30638863; PubMed 
Central PMCID: PMC6412085.  
Hope T. Multiscale imaging of therapeutic antibody distri bution and localization. 
Presented at: 2019 HIV & HBV Cure Forum; Jul 20 -21; Mexico City, Mexico. Accessed 
2020 Apr 14. 
https://www.iasociety.org/Web/WebContent/File/HIV_Cure_Forum_2019/Session5/FT5 -
2Hope.pdf.  
https://www.who.int/health -topics/coronavirus# tab=tab_3 (Carolina WHO checklist 
reference) Incidence of thrombotic complications in critically ill ICU patients with 
COVID -19. 
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, 
Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, 
Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected 
with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497 -
506. doi: 10.1016/S0140 -6736(20)30183 -5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 
Jan 30;: PMID: 31986264; PMCID: PMC7159299.  
Hui KPY, Cheung MC, Perera RAPM, Ng KC, Bui CHT, Ho JCW, Ng MMT, Kuok 
DIT, Shih KC, Tsao SW, Poon LLM, Peiris M, Nicholls JM, Chan MCW. Tropism, 
replication competence, and innate imm une responses of the coronavirus SARS -CoV -2 in 
human respiratory tract and conjunctiva: an analysis in ex -vivo and in -vitro cultures. 
Lancet. 2020 May 07; https://doi.org/10.1016/S2213 -2600(20)30193 -4. Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 83 Hwang IK, Shih WJ, DeCani JS, Statistics In Medicine. Dec 1990 (Volume9, Issue 12 , 
1439 -1445) Group sequential designs using a family of type I error probability spending 
functions . 
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, et al. Safety Update: COVID -19 
Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95. 
https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp
_ft95_6_8.pdf . 
Klok  FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, 
Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H Thromb Res. 2020; 
PMID 32291094 Clinical characteristics of 113 deceased patients with coronavirus 
disease 2019: retrospectiv e study.  
Ko S -Y, Pegu A, Rudicell RS, Yang Z -Y, Joyce MG, Chen X, Wang K, Bao S, Kraemer 
TD, Rath T, Zeng M, Schmidt SD, Todd J -P, Penzak SR, Saunders KO, Nason MC, 
Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ. 2014. Enhanced neonatal Fc 
receptor fu nction improves protection against primate SHIV infection. Nature. 2014 Oct 
30; 514(7524):642 -5. doi: 10.1038/nature13612.  
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong 
JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zha o J, Liu M, Tu W, Chen C, 
Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, 
Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, CowlingBJ, 
Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China , ofNovel 
Coronavirus -Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199 -1207. doi: 
10.1056/NEJMoa2001316. Epub 2020 Jan 29. PubMed PMID: 31995857.  
Lim JJ, Derby MA, Zhang Y, Deng R, Larouche R, Anderson M, Maia M, Carrier S, 
Pelletier I, Girard J,  Kulkarni P, Newton E, Tavel JA. A Phase 1, Randomized, Double -
Blind, Placebo -Controlled, Single -Ascending -Dose Study To Investigate the Safety, 
Tolerability, and Pharmacokinetics of an Anti -Influenza B Virus Monoclonal Antibody, 
MHAB5553A, in Healthy Volu nteers. Antimicrob Agents Chemother. 2017 Jul 
25;61(8):e00279 -17. doi: 10.1128/AAC.00279 -17. PMID: 28559255; PMCID: 
PMC5527589.  
Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W.. Viral 
dynamics in mild and severe cases of COVID -19. Lancet Infect Dis 2020;doi: 
10.1016/S1473 -3099(20)30232 -2.  
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. 
J Pharm Sci. 2004 Nov;93(11):2645 -68. 
NICE. COVID -19 rapid guideline: critical care in adults (NG159). 
https://ww w.nice.org.uk/guidance/ng159, 2020  
NIH COVID -19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/  
Pablo N Perez -Guzman, Anna Daunt, Sujit Mukherjee et al. Clinical characteristics and 
predictors of outcomes of hospitalised patients with COVID -19 in a London NHS Trust: 
a retrospective cohort study (2020), doi: https://doi.org/10.25561/78613  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 84 Petrilli et al, medrxiv N=1999 (hosp) OpenSAFELY (NHS data) N=5683 Deaths REF: 
COVID -19 dashboard, Johns Hopkins 
https://gisanddata.maps.arcgis.com/app s/opsdashboard/index.html  
Pinto D, Park Y, Beltramello M et al. Cross -neutralization of SARS -CoV -2 by a human 
monoclonal SARS -CoV antibody. Nature. Published online May 18, 2020. 
https://doi.org/10.1038/s41586 -020-2349 -y 
Polack FP, Teng MN, Collins PL, Pri nce GA, Exner M, Regele H, Lirman DD, Rabold 
R, Hoffman SJ, Karp CL, Kleeberger SR, Wills -Karp M, Karron RA. A role for immune 
complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002 Sep 
16;196(6):859 -65. doi: 10.1084/jem.20020781. PMID:  12235218; PMCID: 
PMC2194058.  
Powers JH, Bacci ED, Leidy NK, Poon JL, Stringer S, Memoli MJ, et al. Performance of 
the inFLUenza Patient -Reported Outcome (FLU -PRO) Diary in Patients with Influenza -
Like Illness (ILI). PLoS One. 2018 Mar 22;13(3):e0194180. d oi: 
10.1371/journal.pone.0194180. eCollection 2018.  
Powers JH, Bacci ED, Guerrero ML, Leidy NK, Stringer S, Kim K, Memoli MJ, et al. 
Reliability, Validity, and Responsiveness of InFLUenza Patient -Reported Outcome 
(FLU -PRO©) Scores in Influenza -Positive Pat ients. Value Health. 2018 Feb;21(2):210 -
218. doi: 10.1016/j.jval.2017.04.014. Epub 2017 Jun 7.  
Richardson  S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, 
and Outcomes Among 5700 Patients Hospitalized With COVID -19 in the New York City 
Area. JAMA. Published online April 22, 2020. doi:10.1001/jama.2020.6775.  
Wölfel R, Corman VM, Gu ggemos W, et al. Virological assessment of hospitalized 
patients with COVID -2019. Nature. 2020 Apr 01. https://doi.org/10.1038/s41586 -020-
2196 -x 
Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, Ho A, Hung IF, Riley S, Ho LM, 
Lin CK, Tsang T, Lo SV, Lau YL, Le ung GM, Cowling BJ, Malik Peiris JS. The 
infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin 
Infect Dis. 2010 Nov 15;51(10):1184 -91. doi: 10.1086/656740. PMID: 20964521; 
PMCID: PMC3034199.  
Yang H, et al. O0814 Phase IIb st udy evaluating the efficacy and safety of anti -influenza 
A monoclonal antibody, CT -P27, in subjects with acute uncomplicated Influenza A 
Infection. 29th European Congress of Clinical Microbiology and Infectious Diseases. 
Amsterdam, Netherlands. 2019 Apr 13 -16. Poster presentation.  
Yu J, Powers JH 3rd, Vallo D, Falloon J. Evaluation of Efficacy Endpoints for a Phase 
IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient -
Reported Outcomes with Laboratory Confirmation. Value Health. 2 020 Feb;23(2):227 -
235. doi: 10.1016/j.jval.2019.09.2747. Epub 2019 Nov 21.  
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, 
Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk 
factors for mortality  of adult inpatients with COVID -19 in Wuhan, China: a retrospective 
cohort study. Lancet. 2020 Mar 28;395(10229):1054 -1062. doi: 10.1016/S0140 -Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
VIR-7831  
VIR-7831 -5001(GSK Study 214367)  
Vir Biotechnology, Inc Page 85 6736(20)30566 -3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 
28;395(10229):1038. Lancet. 2020 Mar 28;395(10229 ):1038. PubMed PMID: 32171076.  
Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, 
Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. SARS -CoV -2 Viral Load in Upper 
Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Mar 19; 382(12):1177 -
1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19. PubMed PMID: 32074444.  Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
Signature Page for VV-CLIN-000126 v5.0
Signature Page for VV-CLIN-000126 v5.0Approval
21-Jun-2021 17:45:44 GMT+0000Protocol Documentation_Amendment 2___17 Jun 2021 | VV-TMF-15746259 | 2.0
Approved
PPD
PPD